<?xml version="1.0" ?>
<document version="1.8" entity_encoding="single">
  <page number="1">
    <text>**Module 5311 (Special Needs Dentistry)**

*Neurodegenerative disease*

**15 Sep 2025**
**2-4 PM (WA Time)**
**Online**

**Dr David Lim**
Lecturer, Dental School, UWA
BDS (SG), MSc SCD (UCL), PG Dip Con Sed D (KCL), GC Geront (SUSS), Dip ACEdu (SUSS), FiADH, MFTD MFDS RCSEd

Acknowledgements to
Dr Jee-Yun Leung
Ms Lee Yan Shan (Singapore General Hospital)
Dr Daniel Sundaresan
Associate Professor Mina Borromeo
Dr Mathew Lim
Dr Claudia Lopez Silva

**UWA**
PERTH • AUSTRALIA</text>
    <formatted_text>*Neurodegenerative disease*

- 15 Sep 2025
- 2–4 PM (WA Time)
- Online

**Dr David Lim**
Lecturer, Dental School, UWA
BDS (SG), MSc SCD (UCL), PG Dip Con Sed D (KCL), GC Geront (SUSS), Dip ACEdu (SUSS), FiADH, MFTD MFDS RCSEd

Acknowledgements to:

- Dr Jee-Yun Leung
- Ms Lee Yan Shan (Singapore General Hospital)
- Dr Daniel Sundaresan
- Associate Professor Mina Borromeo
- Dr Mathew Lim
- Dr Claudia Lopez Silva</formatted_text>
  </page>
  <page number="2">
    <text/>
  </page>
  <page number="3">
    <text># Learning Objective

1. Understand the specific characteristics and dental needs of individuals with common neurodegenerative diseases (e.g.

2. epilepsy, cerebral palsy, acquired brain injury (stroke/trauma), Parkinson's disease, motor neurone disease, multiple sclerosis, Huntington's disease, spina bifida, including

3. communication strategies, behavioural considerations, and appropriate treatment adaptations to ensure effective dental care

4. + dysphagia</text>
    <formatted_text>1. Understand the specific characteristics and dental needs of individuals with common neurodegenerative diseases (e.g., epilepsy, cerebral palsy, acquired brain injury (stroke/trauma), Parkinson's disease, motor neurone disease, multiple sclerosis, Huntington's disease, spina bifida), including:
    - communication strategies, behavioural considerations, and appropriate treatment adaptations to ensure effective dental care
    - dysphagia</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:07:43" confidence="4" anchor="dysphagia">
    - ==Its effects on dental treatment, oral health, aspiration risk, and dental practice procedures==.</insert>
    </audio_inserts>
  </page>
  <page number="4">
    <text># Dysphagia

• &lt;u&gt;Dysphagia&lt;/u&gt; is difficulty swallowing
1. oropharyngeal dysphagia
2. esophageal dysphagia
3. functional dysphagia
• NOT DYPHASIA</text>
    <formatted_text>Dysphagia is difficulty swallowing.

1. oropharyngeal dysphagia
2. esophageal dysphagia
3. functional dysphagia

&gt; NOT DYSPHAGIA</formatted_text>
  </page>
  <page number="5">
    <text># Death of woman, 73, who choked on ondeh-ondeh a tragic misadventure: Coroner

# Hospital patient dies after being given regular meals instead of soft diet


![The death of a woman who died choking on ondeh-ondeh was found to be a tragic misadventure, the state coroner reported on Sept 6, 2016. PHOTO: ST FILE](L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_550adcd841696b74.webp)
![The death of Mr Simon Lee, who was warded in Ng Teng Fong General Hospital (pictured) in 2018, was ruled unfortunate misadventure. PHOTO: ST FILE](L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_edf07bb44182ed11.webp)</text>
    <formatted_text>*Death of woman, 73, who choked on ondeh-ondeh a tragic misadventure: Coroner*

*Hospital patient dies after being given regular meals instead of soft diet*</formatted_text>
    <images>
      <img order="0" bbox="37,418,460,797" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_550adcd841696b74.webp" caption="The death of a woman who died choking on ondeh-ondeh was found to be a tragic misadventure, the state coroner reported on Sept 6, 2016. PHOTO: ST FILE">
        <description>A close-up photograph of several orange, spherical ondeh-ondeh cakes coated in shredded white coconut and resting on a green banana leaf.</description>
      </img>
      <img order="1" bbox="543,425,953,793" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_edf07bb44182ed11.webp" caption="The death of Mr Simon Lee, who was warded in Ng Teng Fong General Hospital (pictured) in 2018, was ruled unfortunate misadventure. PHOTO: ST FILE">
        <description>Clinical photo: An exterior view of a modern hospital building, identified in the slide text as Ng Teng Fong General Hospital. The image depicts the facility's distinctive curved architecture and glass facade under a blue sky.</description>
      </img>
    </images>
  </page>
  <page number="6">
    <text>**Oral phase**

*   Tongue moves food around mouth
*   Back of tongue raises to prevent premature spillage
*   Teeth grinds and chews food
*   Food moistened with saliva
*   Cohesive bolus formed
*   Tongue pushes it to back of pharynx

A B C D E F G H

Soft palate
Pharynx
Epiglottis
Upper
esophageal
sphincter
Bolus
Tongue
Trachea
Esophagus
Lower
esophageal
sphincter
Stomach

Singapore
General Hospital

![](L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_a8b71b585ecf73a4.webp)</text>
    <formatted_text>- Tongue moves food around mouth
- Back of tongue raises to prevent premature spillage
- Teeth grinds and chews food
- Food moistened with saliva
- Cohesive bolus formed
- Tongue pushes it to back of pharynx

*Diagram labels: soft palate, pharynx, epiglottis, upper esophageal sphincter, bolus, tongue, trachea, esophagus, lower esophageal sphincter, stomach. Panel markers: A B C D E F G H.*</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:03:36" confidence="8" anchor="- Food moistened with saliva - Cohesive bolus formed - Tongue pushes it to back ">

&gt; [!note] Lecturer — Oral Bolus Formation
&gt; The tongue also compresses food against the occlusal surfaces, especially the molars.
&gt;
&gt; - It mixes food with saliva to form a bolus.
&gt; - The bolus is pushed towards the back of the mouth in a wave-like movement.
</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="38,162,368,856" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="diagram" path="L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_a8b71b585ecf73a4.webp">
        <description>A labelled sagittal anatomical diagram of the human head and neck illustrating the oral phase of swallowing. It depicts a cohesive bolus resting on the tongue within the oral cavity, with lines pointing to surrounding structures including the soft palate, pharynx, epiglottis, upper esophageal sphincter, trachea, esophagus, lower esophageal sphincter, and stomach.</description>
      </img>
    </images>
  </page>
  <page number="7">
    <text>A B Č D E F G H

**Pharyngeal phase**

• Swallow reflex initiated
• Tongue blocks oral cavity
• Soft palate blocks nasal cavity
• Vocal folds close

Singapore General Hospital

![Pharyngeal Phase](L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_5cbf4042c5ce1496.webp)</text>
    <formatted_text>- Swallow reflex initiated
- Tongue blocks oral cavity
- Soft palate blocks nasal cavity
- Vocal folds close

*Diagram panel markers: A B C D E F G H.*</formatted_text>
    <images>
      <img order="0" bbox="27,148,365,852" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="figure" path="L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_5cbf4042c5ce1496.webp" caption="Pharyngeal Phase">
        <description>This is a sagittal anatomical illustration of the human head and neck, depicting the pharyngeal phase of swallowing. The diagram shows the tongue raised to contact the palate (blocking the oral cavity), the soft palate elevated (blocking the nasal cavity), and the larynx positioned anteriorly with the epiglottis visible.</description>
      </img>
    </images>
  </page>
  <page number="8">
    <text>A B C D E F G H
Epiglottis

**Pharyngeal phase**
• Epiglottis flips over
• Upper esophageal sphincter opens

Singapore General Hospital

![Pharyngeal Phase](L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_201d76950d9271fc.webp)</text>
    <formatted_text>*Diagram label: epiglottis.*

- Epiglottis flips over
- Upper esophageal sphincter opens</formatted_text>
    <audio_inserts count="4">
      <insert timestamp="00:03:50" confidence="5" anchor="- Epiglottis flips over - Upper esophageal sphincter opens">

&gt; [!note] Lecturer — Pharyngeal Protection
&gt; The swallowing reflex begins at the back of the mouth and in the upper part of the throat. The person also holds their breath during this phase.
</insert>
      <insert timestamp="00:04:35" confidence="6" anchor="#### **Esophageal Phase**  - Larynx moves back to original position - Peristalsi">

&gt; [!note] Lecturer — Swallowing Phases
&gt; Food moves through the esophagus towards the stomach by peristalsis. Problems affecting any of the swallowing phases can result in dysphagia.
</insert>
      <insert timestamp="00:07:23" confidence="11" anchor="### **Complications And Aspiration Pneumonia**  Dysphagia can result in:  - Chok">

&gt; [!note] Lecturer — Choking and Aspiration
&gt; Choking occurs when something becomes stuck, and the person is usually unable to speak because air cannot pass through the throat. Aspiration may be silent.
&gt;
&gt; - Aspiration may present as dribbling of liquid or may involve small dental items entering the lungs through the trachea and right main bronchus.
</insert>
      <insert timestamp="00:11:58" confidence="5" anchor="- Dry secretions on palate of elderly patients  Seek help from Physician / SALT ">

&gt; [!note] Lecturer — Dry Oral Secretions
&gt; Dry secretions in aged-care patients may consist of phlegm, saliva and mucus. They can dry on the soft palate and mucosa and harbour bacteria.
&gt;
&gt; - The secretions can be removed by brushing, while taking care to prevent them from dribbling into the mouth.
</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="37,152,368,851" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="diagram" path="L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_201d76950d9271fc.webp" caption="Pharyngeal Phase">
        <description>A sagittal anatomical illustration of the human head and neck showing the pharyngeal phase of swallowing. The diagram depicts the epiglottis in a flipped position covering the larynx, while the upper esophageal sphincter is shown opening to allow passage into the esophagus.</description>
      </img>
    </images>
  </page>
  <page number="9">
    <text>A B C D E F G H

**Esophageal phase**

• Larynx moves back to original position
• Peristalsis

Singapore General Hospital

![Esophageal Phase](L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_071c7dab12d1365d.webp)</text>
    <formatted_text>- Larynx moves back to original position
- Peristalsis</formatted_text>
    <images>
      <img order="0" bbox="27,149,362,856" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="diagram" path="L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_071c7dab12d1365d.webp" caption="Esophageal Phase">
        <description>Anatomical sagittal cross-section diagram of the head and neck showing the pharynx, larynx, and esophagus with a food bolus in transit. The illustration depicts the esophageal phase of swallowing, highlighting the movement of the bolus down the esophagus towards the stomach.</description>
      </img>
    </images>
  </page>
  <page number="10">
    <text># CAUSES OF DYSPHAGIA

**MUSCULAR DISORDERS**
Affects muscle strength
e.g. muscular dystrophy, myasthenia gravis

**NEUROLOGICAL DISORDERS**
Affects how the brain controls our swallow reflex and muscle movements
e.g. stroke, Parkinson’s disease, Multiple sclerosis

**REDUCED RESPIRATORY FUNCTION**
Affects coordination between breathing and swallowing
e.g. COPD

**AGEING / DECONDITIONING**
Weakened muscles and/or impaired coordination
e.g. prolonged hospital stay

**ANATOMICAL CHANGES**
e.g. obstruction in the throat or esophagus due to cancer, changes after surgery, changes to teeth structure.

**MEDICATION / TREATMENT EFFECTS**
can cause dry mouth
e.g. Xerostomia post radiation

**COGNITIVE CHANGES**
Affects awareness of food and drinks during feeding
e.g. dementia, conditions affecting cognition

**CONGENITAL &amp; DEVELOPMENTAL ISSUES**
Affects anatomy, cognition and feeding posture
e.g. cerebral palsy, learning difficulties, cleft lip and palate</text>
    <formatted_text>#### Muscular Disorders
Affects muscle strength, e.g. muscular dystrophy, myasthenia gravis.

#### Neurological Disorders
Affects how the brain controls our swallow reflex and muscle movements, e.g. stroke, Parkinson's disease, multiple sclerosis.

#### Reduced Respiratory Function
Affects coordination between breathing and swallowing, e.g. COPD.

#### Ageing / Deconditioning
Weakened muscles and/or impaired coordination, e.g. prolonged hospital stay.

#### Anatomical Changes
E.g. obstruction in the throat or esophagus due to cancer, changes after surgery, changes to teeth structure.

#### Medication / Treatment Effects
Can cause dry mouth, e.g. xerostomia post radiation.

#### Cognitive Changes
Affects awareness of food and drinks during feeding, e.g. dementia, conditions affecting cognition.

#### Congenital &amp; Developmental Issues
Affects anatomy, cognition and feeding posture, e.g. cerebral palsy, learning difficulties, cleft lip and palate.</formatted_text>
  </page>
  <page number="11">
    <text>Dysphagia can result in

* Choking
* Aspiration
* Pneumonia

**Mortality ~20%**

Healthy Bronchiole and Alveoli
Trachea
Bronchial tubes
Lung
Bronchiole
Alveoli
Excess mucus
Inflamed bronchiole

Lim 2016, drugs.com

![Pneumonia](L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_e0a19e0c62848474.webp)</text>
    <formatted_text>Dysphagia can result in:

- Choking
- Aspiration
- Pneumonia

&gt; Mortality ~20%

*Lung diagram labels: healthy bronchiole and alveoli; trachea; bronchial tubes; lung; bronchiole; alveoli; excess mucus; inflamed bronchiole.*

*Lim 2016, drugs.com*</formatted_text>
    <images>
      <img order="0" bbox="450,290,955,825" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="diagram" path="L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_e0a19e0c62848474.webp" caption="Pneumonia">
        <description>Labelled anatomical diagram comparing a healthy bronchiole and alveoli with those affected by pneumonia, showing features like excess mucus and an inflamed bronchiole. The left side of the image displays a broader view of the respiratory system, labelling the Trachea, Lung, Bronchial tubes, Bronchiole, and Alveoli.</description>
      </img>
    </images>
  </page>
  <page number="12">
    <text>**Causes of aspiration pneumonia**

Medical/Health Status
Oral/Dental Status
Dysphagia
Aspiration Pneumonia
Feeding/Mode of Nutritional Intake
Reflux
Functional Status &amp; Dependence

Langmore et al. (1998) Singapore General Hospital

![](L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_430fa48a61cf41d6.webp)</text>
    <formatted_text>#### Causes of Aspiration Pneumonia

Diagram labels (factors surrounding aspiration pneumonia):

- Medical/Health Status
- Oral/Dental Status
- Dysphagia
- Feeding/Mode of Nutritional Intake
- Reflux
- Functional Status &amp; Dependence

*Langmore et al. (1998) Singapore General Hospital*</formatted_text>
    <images>
      <img order="0" bbox="84,254,912,844" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="diagram" path="L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_430fa48a61cf41d6.webp">
        <description>A hub-and-spoke diagram illustrating the causes of aspiration pneumonia. A central blue box labeled &quot;Aspiration Pneumonia&quot; is connected by red lines to six surrounding colored boxes representing contributing factors: Medical/Health Status, Oral/Dental Status, Dysphagia, Feeding/Mode of Nutritional Intake, Reflux, and Functional Status &amp; Dependence.</description>
      </img>
    </images>
  </page>
  <page number="13">
    <text>**But... These are the strongest predictors of aspiration pneumonia**

Medical/Health Status
Oral/Dental Status
Dysphagia
Aspiration Pneumonia
Feeding/Mode of Nutritional Intake
Reflux
Functional Status &amp; Dependence

Langmore et al. (1998) Singapore General Hospital

![](L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_c72f57a27f88e9e9.webp)</text>
    <formatted_text>&gt; But... these are the strongest predictors of aspiration pneumonia

Diagram labels (strongest predictors surrounding aspiration pneumonia):

- Medical/Health Status
- Oral/Dental Status
- Dysphagia
- Feeding/Mode of Nutritional Intake
- Reflux
- Functional Status &amp; Dependence

*Langmore et al. (1998) Singapore General Hospital*</formatted_text>
    <images>
      <img order="0" bbox="47,278,915,851" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="diagram" path="L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_c72f57a27f88e9e9.webp">
        <description>A radial diagram illustrating the strongest predictors of aspiration pneumonia, with a central blue node connected to six surrounding boxes. The 'Oral/Dental Status' predictor is highlighted in red and circled by hand-drawn annotation, while other factors like 'Medical/Health Status', 'Dysphagia', and 'Reflux' are shown in grey.</description>
      </img>
    </images>
  </page>
  <page number="14">
    <text># Dysphagia

## Dental Management

*   Oral hygiene against pneumonia
*   Manage caries risk (as a result of dietary modifications)
*   Prosthetic considerations
*   5 “R”s chair side
*   Oral facial exercises/massages
*   Seek help from Physician / SALT / OT

(Chung et al., 2014; Durham et al., 1993, Perez-Lloret et al., 2012; Sakar et al., 2013; Smith et all., 2012; Knipfer et al., 2014; www.kapitex.com)

![](L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_294a91eb802b94b8.webp)
![](L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_9dfb42dcb8b7bb0c.webp)
![](L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_ccb9c74e79ad6dc4.webp)</text>
    <formatted_text>- Oral hygiene against pneumonia
- Manage caries risk (as a result of dietary modifications)
- Prosthetic considerations
- 5 &quot;R&quot;s chair side
- Orofacial exercises/massages
- Seek help from Physician / SALT / OT

*Chung et al., 2014; Durham et al., 1993, Perez-Lloret et al., 2012; Sakar et al., 2013; Smith et all., 2012; Knipfer et al., 2014; www.kapitex.com*</formatted_text>
    <images>
      <img order="0" bbox="502,354,750,546" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_294a91eb802b94b8.webp">
        <description>A studio product photograph showing four different types of adaptive drinking aids or cups arranged against a blue background. The items include a grey cup with two handles and a cutout rim, a translucent white cup with an angled rim, a tall opaque white pitcher-style container, and a smaller teal cup with a curved rim.</description>
      </img>
      <img order="1" bbox="788,309,970,548" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_9dfb42dcb8b7bb0c.webp">
        <description>Clinical photo: A woman holding a handheld spirometer or respiratory training device to her mouth, demonstrating an oral-facial exercise or breathing technique.</description>
      </img>
      <img order="2" bbox="729,605,978,833" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_ccb9c74e79ad6dc4.webp">
        <description>Clinical photo: A dental prosthesis, likely a removable partial denture or obturator, featuring three artificial teeth attached to a pink acrylic base with extended flanges. The device is resting on a blue surgical drape.</description>
      </img>
    </images>
  </page>
  <page number="15">
    <text>Oral hygiene against pneumonia

**Aspiration pneumonia/ ?Health care associated pneumonia**

*   Leading cause of death and hospitalisation in nursing homes
*   Represents about 1% of Australian deaths
*   Dysphagia recognised risk factor – insufficient as sole cause
*   Also patients who are immobile, altered consciousness, comorbidities, increasing age
*   Oral health may be a predictor of respiratory-related deaths
*   Nocturnal denture wearing associated with 2.3 fold increase in risk
*   Periodontal disease increases risk by 3.9 times
*   Improved oral hygiene could prevent one in ten deaths</text>
    <formatted_text>**Aspiration pneumonia / ?Health care associated pneumonia**

- Leading cause of death and hospitalisation in nursing homes
- Represents about 1% of Australian deaths
- Dysphagia recognised risk factor – insufficient as sole cause
- Also patients who are immobile, altered consciousness, comorbidities, increasing age
- Oral health may be a predictor of respiratory-related deaths
- Nocturnal denture wearing associated with 2.3 fold increase in risk
- Periodontal disease increases risk by 3.9 times
- Improved oral hygiene could prevent one in ten deaths</formatted_text>
  </page>
  <page number="16">
    <text>Dry secretions on
palate of elderly patients</text>
    <formatted_text>Dry secretions on palate of elderly patients</formatted_text>
  </page>
  <page number="17">
    <text>Seek help from
Physician / SALT / OT

Oral hygiene against pneumonia

IDDSI framework

• International Diet Dysphagia
Standardization Initiative
https://idddsi.org/

• A global standard with
descriptions and testing methods
for texture-modified foods and
fluids for people with dysphagia.

The IDDSI Framework
Providing a common terminology for describing food textures and drink
thicknesses to improve safety for individuals with swallowing difficulties.

FOODS
TRANSITIONAL FOODS
REGULAR
EASY TO CHEW
SOFT &amp; BITE-SIZED
MINCED &amp; MOIST
PUREED
LIQUIDISED
7
6
5
4 EXTREMELY THICK
3 MODERATELY THICK
2 MILDLY THICK
1 SLIGHTLY THICK
0
THIN
DRINKS

Singapore
General Hospital

![The IDDSI Framework Providing a common terminology for describing food textures and drink thicknesses to improve safety for individuals with swallowing difficulties.](L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_ffcf2f88bd735efe.webp)
![](L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_8c67821b8a4ce45b.webp)</text>
    <formatted_text>Seek help from Physician / SALT / OT

#### IDDSI Framework

- International Diet Dysphagia Standardization Initiative — https://idddsi.org/
- A global standard with descriptions and testing methods for texture-modified foods and fluids for people with dysphagia.

The IDDSI Framework provides a common terminology for describing food textures and drink thicknesses to improve safety for individuals with swallowing difficulties.

**Foods (levels 7–4):**

1. Level 7 — Regular
2. Level 7 — Easy to Chew
3. Level 6 — Soft &amp; Bite-Sized
4. Level 5 — Minced &amp; Moist
5. Level 4 — Pureed
6. Transitional Foods
7. Liquidised

**Drinks (levels 0–4):**

1. Level 0 — Thin
2. Level 1 — Slightly Thick
3. Level 2 — Mildly Thick
4. Level 3 — Moderately Thick
5. Level 4 — Extremely Thick

*Singapore General Hospital*</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:13:12" confidence="7" anchor="The IDDSI Framework provides a common terminology for describing food textures a">

&gt; [!note] Lecturer — Modified Diets
&gt; Some patients may require thickened fluids; a patient with Parkinson's disease, for example, may need thickener because of poor swallowing. Fortified or thickened foods may be sticky, remain around or between the teeth, and be difficult to brush away.
&gt;
&gt; - Dietary modifications combined with dry mouth can increase the risk of dental caries and periodontal problems.
</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="483,60,958,295" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_ffcf2f88bd735efe.webp" caption="The IDDSI Framework Providing a common terminology for describing food textures and drink thicknesses to improve safety for individuals with swallowing difficulties.">
        <description>A composite photograph showing specialized adaptive drinking vessels on the left and an elderly woman using a nose-and-mouth cup on the right. The image illustrates assistive devices designed to help individuals with swallowing difficulties or physical limitations drink safely.</description>
      </img>
      <img order="1" bbox="502,418,967,934" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="diagram" path="L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_8c67821b8a4ce45b.webp">
        <description>This diagram illustrates the IDDSI (International Dysphagia Diet Standardisation Initiative) framework, displaying a funnel-shaped chart that categorizes foods and drinks into levels 0 through 7 based on texture and thickness. The upper inverted section lists food textures from Level 7 (Regular) down to Level 3 (Liquidised), while the lower upright section lists drink thicknesses from Level 0 (Thin) up to Level 4 (Extremely Thick). A side label indicates 'Transitional Foods' corresponding to the upper levels.</description>
      </img>
    </images>
  </page>
  <page number="18">
    <text>Management of impaired swallowing and oral implications

Manage caries risk (as a result of dietary modifications)

Many of the strategies can increase risk of decay and periodontal disease
• Fortified diets and supplements
• Altered food texture
• Food thickeners
• Management of sialorrhea
• Crushed medications

INGREDIENTS
Maltodextrin (Corn, Potato), Thickener (Xanthan Gum), Mineral Salt (Potassium Chloride). Made on equipment that also processes products containing Milk.

![INGREDIENTS Maltodextrin (Corn, Potato), Thickener (Xanthan Gum), Mineral Salt (Potassium Chloride). Made on equipment that also processes products containing Milk.](L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_f55d17a2867cd142.webp)</text>
    <formatted_text>Management of impaired swallowing and oral implications

Many of the strategies can increase risk of decay and periodontal disease:

- Fortified diets and supplements
- Altered food texture
- Food thickeners
- Management of sialorrhea
- Crushed medications

&gt; Ingredient label example: Maltodextrin (Corn, Potato), Thickener (Xanthan Gum), Mineral Salt (Potassium Chloride). Made on equipment that also processes products containing Milk.</formatted_text>
    <images>
      <img order="0" bbox="559,339,986,619" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_f55d17a2867cd142.webp" caption="INGREDIENTS Maltodextrin (Corn, Potato), Thickener (Xanthan Gum), Mineral Salt (Potassium Chloride). Made on equipment that also processes products containing Milk.">
        <description>A product photo showing a canister and single-serve sachet of Nestlé Resource ThickenUp instant food and drink thickener alongside two cartons of Nestlé Sustain nutritional supplements (Dutch Chocolate and Vanilla flavors).</description>
      </img>
    </images>
  </page>
  <page number="19">
    <text>Prosthetic considerations

Loose dentures affect function
**risk of ingestion**
* speech
* **&amp; aspiration**
* mastication
* swallowing

sciencedirect.com, Gachabayov et al., 2015</text>
    <formatted_text>Loose dentures affect function:

- speech
- mastication
- swallowing
- **risk of ingestion &amp; aspiration**

*sciencedirect.com, Gachabayov et al., 2015*</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:14:03" confidence="6" anchor="Loose dentures affect function:  - speech - mastication - swallowing - **risk of">

&gt; [!note] Lecturer — Denture Design
&gt; Palatal coverage may reduce the patient’s ability to feel food during the oral and oropharyngeal phases. Small unilateral dentures and single-tooth dentures are rarely prescribed because they may be ingested or aspirated.
</insert>
    </audio_inserts>
  </page>
  <page number="20">
    <text>Effective vs non-
effective dentures on 
swallowing

tongue is free to ‘pack’ 
bolus &amp; free to swallow

increased distribution 
of food

prevents cheek/lip 
biting

stabilisation of 
mandible during 
swallowing

From SEMD by Dr Jiro Abe

Prosthetic considerations

Suction Effectiveness

Ill-fit Mandibular denture
TCR 11:02:52:10</text>
    <formatted_text>#### Effective vs Non-Effective Dentures on Swallowing

An effective denture allows:

- tongue to be free to 'pack' bolus &amp; free to swallow
- increased distribution of food
- prevents cheek/lip biting
- stabilisation of mandible during swallowing

*From SEMD by Dr Jiro Abe*

#### Suction Effectiveness

- Ill-fit mandibular denture — *TCR 11:02:52:10*</formatted_text>
  </page>
  <page number="21">
    <text># Palatal Augmentation may help swallowing
## Prosthetic considerations

![](L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_b33e2b74ed8f443a.webp)
![](L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_169703a950aef36c.webp)</text>
    <formatted_text>Palatal augmentation may help swallowing.</formatted_text>
    <images>
      <img order="0" bbox="283,210,437,382" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="diagram" path="L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_b33e2b74ed8f443a.webp">
        <description>A simple hand-drawn schematic of a dental arch or palate, viewed from above. An arrow points to the central area of the hard palate, indicating the site for augmentation.</description>
      </img>
      <img order="1" bbox="180,528,769,936" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_169703a950aef36c.webp">
        <description>Clinical photograph showing two views of a maxillary dental prosthesis or cast, one with the palatal surface intact and the other (right) featuring a large cutout window in the palate. The right image reveals a metallic framework underneath the yellow base material, illustrating a prosthetic design modification such as a palatal augmentation or obturator.</description>
      </img>
    </images>
  </page>
  <page number="22">
    <text>5 “R”s chair side

Dysphagia special care chair side

* Rubber dam
* Reduce aerosol/fluids/foam
* Recline no more that 45*
* Recall if fever, shortness of breath
* Respect the patient (e.g. stop signals)

![](L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_337ceb0d091617da.webp)</text>
    <formatted_text>- Rubber dam
- Reduce aerosol/fluids/foam
- Recline no more than 45°
- Recall if fever, shortness of breath
- Respect the patient (e.g. stop signals)</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:17:46" confidence="8" anchor="- Recline no more than 45° - Recall if fever, shortness of breath - Respect the ">

&gt; [!note] Lecturer — Chair-Side Safety
&gt; Fever, usually within two or three days, and shortness of breath may be signs of pneumonia. If a patient is anxious, moving significantly or not confident about proceeding, treatment may need to be reduced or postponed.
</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="134,736,453,999" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_337ceb0d091617da.webp">
        <description>Clinical photo showing a green rubber dam with a metal frame being held in front of a patient. A yellow arrow points to the center of the sheet, indicating the area where teeth would be isolated.</description>
      </img>
    </images>
  </page>
  <page number="23">
    <text>* 5 “R”s chair side

# Dysphagia special care chair side</text>
    <formatted_text>Dysphagia special care chair side</formatted_text>
  </page>
  <page number="24">
    <text>Levels of Oral Health Care

Orofacial training principles:

THE SPHINX SMILE
GET rid of your smile lines. Smile by lifting the corner of your mouth up and inward, but keep your eyes neutral. Repeat three or four times.

THE SATCHMO
SATCHMO keeps your cheeks firm. Pull up both cheeks with site, then transfer the air from cheek to cheek. Alternate from side to side until you've out o' breath. Repeat three times.

MARILYN
MARILYN smooths your brow. Widen your eyes without wrinkling your brow, then focus on a point on the horizon for five to ten seconds. Repeat four times.

SURPRISE ME

SMILING FISH FACE
PUPPET FACE

lip pucker
tongue over bottom lip
cheek puff left

pinterest.com
Ieto et al effects of oropharyngeal exercises on snoring

![1) push the tip of the tongue against the hard palate and slide the tongue backward (20 times)](L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_6e0ec2ffdc7ce9b7.webp)
![3) force the back of the tongue against the floor of the mouth while keeping the tip of the tongue in contact with the inferior incisive teeth (10 times)](L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_e00dbaba45fcce4a.webp)
![2) suck the tongue upward against the palate, pressing the entire tongue against the palate (20 times)](L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_7f337735d5db0b3c.webp)
![(5) recruitment of the buccinator muscle against the finger that is introduced in the oral cavity, pressing the buccinator muscle outward (10 times each side)](L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_c83e652b86fc37d8.webp)
![4) elevation of the soft palate and uvula (20 times)](L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_c96c46326c936423.webp)
![(6) alternate bilateral chewing and deglutition using the tongue in the palate, without perioral contraction, whenever feeding.](L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_9422b70d461df0f4.webp)
![MARILYN SURPRISE ME SMILING FISH FACE PUPPET FACE](L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_dba4e7e404de4f78.webp)</text>
    <formatted_text>#### Levels of Oral Health Care — Orofacial Training Principles

- **The Sphinx Smile** — Get rid of your smile lines. Smile by lifting the corner of your mouth up and inward, but keep your eyes neutral. Repeat three or four times.
- **The Satchmo** — Satchmo keeps your cheeks firm. Pull up both cheeks with air, then transfer the air from cheek to cheek. Alternate from side to side until you're out of breath. Repeat three times.
- **Marilyn** — Marilyn smooths your brow. Widen your eyes without wrinkling your brow, then focus on a point on the horizon for five to ten seconds. Repeat four times.
- Surprise me
- Smiling fish face
- Puppet face
- Lip pucker
- Tongue over bottom lip
- Cheek puff left

*pinterest.com; Ieto et al., effects of oropharyngeal exercises on snoring*</formatted_text>
    <images>
      <img order="0" bbox="60,398,194,519" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_6e0ec2ffdc7ce9b7.webp" caption="1) push the tip of the tongue against the hard palate and slide the tongue backward (20 times)">
        <description>Clinical photograph showing the inferior surface of an extended tongue with the tip curled upward against the upper teeth. This image illustrates the first orofacial training exercise, where the tongue tip is pushed against the hard palate and slid backward.</description>
      </img>
      <img order="1" bbox="62,537,194,678" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_e00dbaba45fcce4a.webp" caption="3) force the back of the tongue against the floor of the mouth while keeping the tip of the tongue in contact with the inferior incisive teeth (10 times)">
        <description>Clinical photo: A close-up view of an open mouth demonstrating the tongue's position for a specific orofacial exercise. The tip of the tongue is shown in contact with the lower incisive teeth, while the back of the tongue is depressed against the floor of the mouth.</description>
      </img>
      <img order="2" bbox="415,402,548,525" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_7f337735d5db0b3c.webp" caption="2) suck the tongue upward against the palate, pressing the entire tongue against the palate (20 times)">
        <description>Clinical photo showing the open oral cavity of a patient with the tongue pressed upward against the hard palate. The image illustrates the execution of an orofacial exercise, specifically demonstrating the suction and elevation of the entire tongue surface to contact the roof of the mouth.</description>
      </img>
      <img order="3" bbox="61,692,195,825" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_c83e652b86fc37d8.webp" caption="(5) recruitment of the buccinator muscle against the finger that is introduced in the oral cavity, pressing the buccinator muscle outward (10 times each side)">
        <description>A clinical photograph showing a gloved finger inserted into the oral cavity to press the cheek outward, illustrating the recruitment of the buccinator muscle against the resistance.</description>
      </img>
      <img order="4" bbox="414,549,549,677" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_c96c46326c936423.webp" caption="4) elevation of the soft palate and uvula (20 times)">
        <description>Clinical photo: An intraoral view showing the elevation of the soft palate and uvula, with the tongue depressed against the floor of the mouth to expose the posterior pharyngeal wall. This image illustrates the execution of exercise number 4 from the slide's list of orofacial training principles.</description>
      </img>
      <img order="5" bbox="419,712,551,824" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_9422b70d461df0f4.webp" caption="(6) alternate bilateral chewing and deglutition using the tongue in the palate, without perioral contraction, whenever feeding.">
        <description>Clinical photograph: a close-up profile view of the lower face, showing the nose, lips, and chin area. The image captures the perioral region in a neutral state, likely illustrating the facial muscles involved in the exercise.</description>
      </img>
      <img order="6" bbox="736,400,969,876" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="figure" path="L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_dba4e7e404de4f78.webp" caption="MARILYN SURPRISE ME SMILING FISH FACE PUPPET FACE">
        <description>A grid of instructional photographs showing a woman demonstrating various facial exercises. The crop captures four specific poses labeled MARILYN, SURPRISE ME, SMILING FISH FACE, and PUPPET FACE, each accompanied by descriptive text on how to perform the movement.</description>
      </img>
    </images>
  </page>
  <page number="25">
    <text># Learning Objective

1. Understand the specific characteristics and dental needs of individuals with common neurodegenerative diseases (e.g.

2. epilepsy, cerebral palsy, acquired brain injury (stroke/trauma), Parkinson's disease, motor neurone disease, multiple sclerosis, Huntington's disease, spina bifida, including

3. communication strategies, behavioural considerations, and appropriate treatment adaptations to ensure effective dental care

4. + dysphagia</text>
    <formatted_text>1. Understand the specific characteristics and dental needs of individuals with common neurodegenerative diseases (e.g. epilepsy, cerebral palsy, acquired brain injury (stroke/trauma), Parkinson's disease, motor neurone disease, multiple sclerosis, Huntington's disease, spina bifida), including:
   - communication strategies
   - behavioural considerations
   - appropriate treatment adaptations to ensure effective dental care
   - dysphagia</formatted_text>
  </page>
  <page number="26">
    <text>&lt;table&gt;
  &lt;tr&gt;
    &lt;th&gt;&lt;/th&gt;
    &lt;th&gt;Where to find basic info&lt;/th&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Epilepsy&lt;/td&gt;
    &lt;td&gt;Slides&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Cerebral palsy&lt;/td&gt;
    &lt;td&gt;Slides&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Stroke&lt;/td&gt;
    &lt;td&gt;Dougall &amp;amp; Fiske 2008 https://www.nature.com/articles/sj.bdj.2008.891&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Parkinson’s disease&lt;/td&gt;
    &lt;td&gt;Slides&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Motor neurone disease&lt;/td&gt;
    &lt;td&gt;Tay &amp;amp; Borromeo 2014 https://onlinelibrary.wiley.com/doi/10.1111/&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Multiple sclerosis&lt;/td&gt;
    &lt;td&gt;Slides&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Huntington’s&lt;/td&gt;
    &lt;td&gt;Slides&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Acquired brain injury&lt;/td&gt;
    &lt;td&gt;Kothari et al., 2020 https://www.tandfonline.com/doi/epdf/&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Spina Bifida&lt;/td&gt;
    &lt;td&gt;Gary et al., 2012 https://onlinelibrary.wiley.com/doi/10.1111/&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

![](L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_7ca05d295a839c11.webp)</text>
    <formatted_text>#### Where to Find Basic Info

| Condition | Where to find basic info |
| --- | --- |
| Epilepsy | Slides |
| Cerebral palsy | Slides |
| Stroke | Dougall &amp; Fiske 2008 — https://www.nature.com/articles/sj.bdj.2008.891 |
| Parkinson's disease | Slides |
| Motor neurone disease | Tay &amp; Borromeo 2014 — https://onlinelibrary.wiley.com/doi/10.1111/ |
| Multiple sclerosis | Slides |
| Huntington's | Slides |
| Acquired brain injury | Kothari et al., 2020 — https://www.tandfonline.com/doi/epdf/ |
| Spina Bifida | Gary et al., 2012 — https://onlinelibrary.wiley.com/doi/10.1111/ |</formatted_text>
    <images>
      <img order="0" bbox="62,83,938,947" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_7ca05d295a839c11.webp">
        <description>A two-column table listing various neurological and physical conditions (such as Epilepsy, Stroke, and Parkinson's disease) alongside sources for basic information, which include 'Slides' or specific academic references with URLs.</description>
      </img>
    </images>
  </page>
  <page number="27">
    <text># How to learn about conditions

&lt;table&gt;
  &lt;thead&gt;
    &lt;tr&gt;
      &lt;th&gt;&lt;/th&gt;
      &lt;th&gt;Epilepsy&lt;/th&gt;
      &lt;th&gt;Cerebral palsy, stroke, acquired brain injury,, parkinson, multiple sclerosis,&lt;/th&gt;
    &lt;/tr&gt;
  &lt;/thead&gt;
  &lt;tbody&gt;
    &lt;tr&gt;
      &lt;td&gt;Definition&lt;/td&gt;
      &lt;td&gt;&lt;/td&gt;
      &lt;td&gt;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;Epidemiology&lt;/td&gt;
      &lt;td&gt;&lt;/td&gt;
      &lt;td&gt;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;Clinical features&lt;/td&gt;
      &lt;td&gt;&lt;/td&gt;
      &lt;td&gt;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;Aetiopathogensis&lt;/td&gt;
      &lt;td&gt;&lt;/td&gt;
      &lt;td&gt;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;Diagnosis / Types&lt;/td&gt;
      &lt;td&gt;&lt;/td&gt;
      &lt;td&gt;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;Management / Prognosis&lt;/td&gt;
      &lt;td&gt;&lt;/td&gt;
      &lt;td&gt;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;Oral findings&lt;/td&gt;
      &lt;td&gt;&lt;/td&gt;
      &lt;td&gt;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;Emergencies&lt;/td&gt;
      &lt;td&gt;&lt;/td&gt;
      &lt;td&gt;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;ACCESS&lt;/td&gt;
      &lt;td&gt;&lt;/td&gt;
      &lt;td&gt;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;/tbody&gt;
&lt;/table&gt;

![](L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_8cf6fb020116c250.webp)</text>
    <formatted_text>#### How to Learn About Conditions

Complete the following topics for each condition group:

| | Epilepsy | Cerebral palsy, stroke, acquired brain injury, Parkinson's, multiple sclerosis |
| --- | --- | --- |
| Definition | | |
| Epidemiology | | |
| Clinical features | | |
| Aetiopathogenesis | | |
| Diagnosis / Types | | |
| Management / Prognosis | | |
| Oral findings | | |
| Emergencies | | |
| ACCESS | | |</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:21:43" confidence="7" anchor="| Management / Prognosis | | | | Oral findings | | | | Emergencies | | | | ACCES">

&gt; [!note] Lecturer — Condition Review
&gt; The conditions should be reviewed systematically using a table or spreadsheet for each condition.
&gt;
&gt; - Include epidemiology and prevalence, mechanisms of disease, subtypes, and management and treatment alongside the existing review topics.
&gt; - Stroke, acquired brain injury, and spina bifida were not covered in detail because they are addressed in other lectures; motor neurone disease, acquired brain injury, and spina bifida require further review.
&gt; - For epilepsy, status epilepticus is an important emergency to understand.
</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="41,158,957,991" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_8cf6fb020116c250.webp">
        <description>Table: A comparison matrix with rows for Definition, Epidemiology, Clinical features, Aetiopathogensis, Diagnosis / Types, Management / Prognosis, Oral findings, Emergencies, and ACCESS. The columns are headed by 'Epilepsy' and a group of conditions including Cerebral palsy, stroke, acquired brain injury, parkinson, and multiple sclerosis.</description>
      </img>
    </images>
  </page>
  <page number="28">
    <text>What is epilepsy?

**Group of disorders of brain function causing LOSS OF CONSCIOUSNESS and usually LOSS OF MOTOR AND SENSORY FUNCTION.**

**General term for conditions with recurring SEIZURES.**

**Prevalence: 1% of the population**

**Young, mentally or physically impaired usually affected.**</text>
    <formatted_text>A group of disorders of brain function causing loss of consciousness and usually loss of motor and sensory function.

A general term for conditions with recurring seizures.

- **Prevalence:** 1% of the population
- Young, mentally or physically impaired usually affected.</formatted_text>
  </page>
  <page number="29">
    <text>WHAT IS epilepsy?

World Health
Organization

A NEUROLOGICAL CONDITION
characterized by recurrent seizures

Seizures are due to
brief disturbances in the
electrical functions
of the brain

Epilepsy affects people of all ages

NEUROLOGICAL
INFECTIONS

STROKE

HEAD
INJURIES

GENETIC
BASIS

BRAIN
TUMOURS

CAUSES

BRAIN DAMAGE
FROM PRENATAL OR
PERINATAL CAUSES

?
UNKNOWN
IN MANY CASES

NOT
CONTAGIOUS

![](L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_455323391893fb9d.webp)</text>
    <formatted_text>A neurological condition characterized by recurrent seizures (World Health Organization).

Seizures are due to brief disturbances in the electrical functions of the brain. Epilepsy affects people of all ages.

#### Causes

- Neurological infections
- Stroke
- Head injuries
- Genetic basis
- Brain tumours
- Brain damage from prenatal or perinatal causes
- Unknown in many cases

&gt; Epilepsy is not contagious.</formatted_text>
    <audio_inserts count="2">
      <insert timestamp="00:23:09" confidence="7" anchor="Seizures are due to brief disturbances in the electrical functions of the brain.">

&gt; [!note] Lecturer — Diagnosis and Seizures
&gt; Epilepsy is the diagnosis, whereas a seizure or fit is its clinical feature. A diagnosis generally requires at least one or two seizures, similar to the distinction between asthma and breathlessness.
</insert>
      <insert timestamp="00:23:32" confidence="4" anchor="- Unknown in many cases">
- ==Approximately one-third of people with intellectual disability were stated to have epilepsy.==</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="505,223,968,772" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="diagram" path="L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_455323391893fb9d.webp">
        <description>This diagram illustrates the various causes of epilepsy, radiating from a central silhouette of a head containing a brain labeled &quot;CAUSES&quot;. Surrounding blue circles identify specific etiologies including neurological infections, stroke, head injuries, genetic basis, brain tumours, and brain damage from prenatal or perinatal causes, along with an &quot;UNKNOWN IN MANY CASES&quot; category and a crossed-out circle indicating it is not contagious.</description>
      </img>
    </images>
  </page>
  <page number="30">
    <text>Types of epilepsy

Variety of patterns.
Generalised-
• Tonic clonic: LOC, distinct phases, under 5 mins
• Absences: brief period of unresponsiveness &lt;30s</text>
    <formatted_text>A variety of patterns.

#### Generalised

- Tonic clonic: loss of consciousness, distinct phases, under 5 mins
- Absences: brief period of unresponsiveness &lt;30s</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:23:56" confidence="4" anchor="- Absences: brief period of unresponsiveness &lt;30s">
- ==The term grand mal is now more commonly referred to as a tonic-clonic seizure, and absence seizures were previously called petit mal seizures.==</insert>
    </audio_inserts>
  </page>
  <page number="31">
    <text>Types of epilepsy

Variety of patterns.
Partial seizures-
• Simple (Jacksonian epilepsy) - motor, sensory, or psychic features
• Complex (Temporal lobe epilepsy) - impaired consciousness + repetitive acts</text>
    <formatted_text>A variety of patterns.

#### Partial seizures

- Simple (Jacksonian epilepsy) — motor, sensory, or psychic features
- Complex (Temporal lobe epilepsy) — impaired consciousness + repetitive acts</formatted_text>
  </page>
  <page number="32">
    <text>youtube - monicque1979able</text>
    <formatted_text>youtube - monicque1979able</formatted_text>
  </page>
  <page number="33">
    <text>TYPICAL SEIZURE [ FIT ]: GRAND MAL SEIZURE

Defined sequence:
Warning or ‘**AURA**’ – can be mood change, irritability, brief hallucination, headache

**TONIC PHASE:**
► Total body tonic spasm
► Loss of consciousness
► Fall, danger of injury
► Pallor, dilation of pupils, head and spine extension
► Glottic and respiratory muscle spasm
► May be incontinence and biting of lips or tongue</text>
    <formatted_text>Typical seizure [fit]: grand mal seizure

Defined sequence:

Warning or 'AURA' — can be mood change, irritability, brief hallucination, headache.

#### Tonic phase

- Total body tonic spasm
- Loss of consciousness
- Fall, danger of injury
- Pallor, dilation of pupils, head and spine extension
- Glottic and respiratory muscle spasm
- May be incontinence and biting of lips or tongue</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:26:22" confidence="2" anchor="Warning or 'AURA' — can be mood change, irritability, brief hallucination, heada">
- ==An aura may also involve smelling something unusual.==</insert>
    </audio_inserts>
  </page>
  <page number="34">
    <text>CLONIC PHASE:
▶ Follows tonic phase
▶ Repetitive jerking movements of trunk, limbs, tongue, lips
▶ Profuse salivation
▶ Bruxism, tongue biting, vomiting
▶ Tachycardia, hypertension, flushing
▶ Clonus is followed by flaccid semi-coma for 10-15 minutes</text>
    <formatted_text>#### Clonic phase

- Follows tonic phase
- Repetitive jerking movements of trunk, limbs, tongue, lips
- Profuse salivation
- Bruxism, tongue biting, vomiting
- Tachycardia, hypertension, flushing
- Clonus is followed by flaccid semi-coma for 10-15 minutes</formatted_text>
  </page>
  <page number="35">
    <text>Afterwards.......

*   Confusion and headaches
*   Patient may sleep for up to 12 hours or more before full recovery. Most seizures end without mishap.

**Major effects:**

*   trauma,
*   respiratory embarrassment
*   brain damage
*   **STATUS EPILEPTICUS** [ Alternate tonic-clonic phases repeatedly without regaining of consciousness.] Associated with inhalation of vomit and saliva, brain damage or death.</text>
    <formatted_text>#### Afterwards

- Confusion and headaches
- Patient may sleep for up to 12 hours or more before full recovery. Most seizures end without mishap.

#### Major effects

- Trauma
- Respiratory embarrassment
- Brain damage
- **Status epilepticus** — alternate tonic-clonic phases repeatedly without regaining of consciousness. Associated with inhalation of vomit and saliva, brain damage or death.</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:27:41" confidence="8" anchor="**Status epilepticus** — alternate tonic-clonic phases repeatedly without regain">

&gt; [!note] Lecturer — Airway During Seizures
&gt; During a prolonged seizure, respiratory embarrassment may include difficulty breathing and reduced blood oxygen. Suctioning is generally avoided because the patient may bite off part of the suction device and aspirate it; the head should instead be tilted downwards or sideways so saliva and fluid can flow out naturally.
</insert>
    </audio_inserts>
  </page>
  <page number="36">
    <text>Petit mal ( absence seizures)

In children
Sudden transient arrest of movement, attention, speech
[ABSENCE]</text>
    <formatted_text>Petit mal (absence seizures)

In children: sudden transient arrest of movement, attention, speech [absence].</formatted_text>
  </page>
  <page number="37">
    <text>GENERAL MANAGEMENT OF TONIC-CLONIC EPILPESY

**Prophylactic anticonvulsants e.g. Carbamazepine, Phenytoin, Lamotrigine**

**ORO-DENTAL COMPLICATIONS:**
*   Injuries caused by fit
*   Laceration of tongue or buccal mucosa
*   Injuries to face[ lacerations, haematomas, fractures]
*   Subluxation or loss of teeth
*   Phenytoin- causes gingival fibrous hyperplasia of interdental papillae</text>
    <formatted_text>Prophylactic anticonvulsants e.g. Carbamazepine, Phenytoin, Lamotrigine.

#### Oro-dental complications

- Injuries caused by fit
- Laceration of tongue or buccal mucosa
- Injuries to face (lacerations, haematomas, fractures)
- Subluxation or loss of teeth
- Phenytoin — causes gingival fibrous hyperplasia of interdental papillae</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:11:18" confidence="4" anchor="- Phenytoin — causes gingival fibrous hyperplasia of interdental papillae">
- ==Poor oral hygiene can increase gingival enlargement, so good brushing is important to reduce this risk.==</insert>
    </audio_inserts>
  </page>
  <page number="38">
    <text># DENTAL CONSIDERATIONS

**Epileptics have good and bad phases**

Dental treatment preferably in good phase when attacks are infrequent [ important to get detailed history. Ask “**When was the last seizure?**”

Schedule appointment in early hours of the day-Short sessions

Avoid known triggers like bright lights [ keep dental light out of patient’s eyes, use dark safety glasses] and extreme noises

Keep oral cavity free of debris, keep equipment and instruments away from area around patient.</text>
    <formatted_text>Epileptics have good and bad phases.

Dental treatment preferably in good phase when attacks are infrequent — important to get detailed history. Ask: &quot;**When was the last seizure?**&quot;

- Schedule appointment in early hours of the day — short sessions
- Avoid known triggers like bright lights (keep dental light out of patient's eyes, use dark safety glasses) and extreme noises
- Keep oral cavity free of debris; keep equipment and instruments away from area around patient</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:34:34" confidence="7" anchor="- Keep oral cavity free of debris; keep equipment and instruments away from area">
- ==Some patients experience seizures early in the morning, in the afternoon, or when tired; these patterns should be identified when scheduling appointments.==
- ==Small, ill-fitting dentures should be avoided because they may dislodge during a seizure.==
- ==Prolonged use of sodium valproate may increase bleeding risk.==</insert>
    </audio_inserts>
  </page>
  <page number="39">
    <text>If patient has seizure in dental chair

*   Treatment should be stopped and dental instruments, removable prostheses [only if possible] and cotton wool rolls/gauze rolls should be removed immediately from the mouth
*   Help patient into the supine position. Loosen tight clothing
*   Not necessary to restrain the patient or move him/her to the floor; neither is it necessary to place an object in the patient’s mouth (e.g. to stop them swallowing their tongue).
*   Preventing injury is the main goal
*   Call for emergency help [ambulance]
*   Some patients fall into a deep sleep after seizure. If so, monitor closely especially for airway obstruction
*   Lie patient on side to maintain airway – face rotated to allow vomit to be expelled from mouth and prevent inhalation.
*   If the seizure lasts more than 5 minutes and recurs, drug administration is required. [ usually midazolam -buccal, rectal or IV.]
*   After the patient regains consciousness, he/she should be sent home to rest. Treatment should be postponed until the patient feels well again</text>
    <formatted_text>- Treatment should be stopped and dental instruments, removable prostheses (only if possible) and cotton wool rolls/gauze rolls should be removed immediately from the mouth
- Help patient into the supine position. Loosen tight clothing
- Not necessary to restrain the patient or move him/her to the floor; neither is it necessary to place an object in the patient's mouth (e.g. to stop them swallowing their tongue)
- Preventing injury is the main goal
- Call for emergency help (ambulance)
- Some patients fall into a deep sleep after seizure. If so, monitor closely especially for airway obstruction
- Lie patient on side to maintain airway — face rotated to allow vomit to be expelled from mouth and prevent inhalation
- If the seizure lasts more than 5 minutes and recurs, drug administration is required (usually midazolam — buccal, rectal or IV)
- After the patient regains consciousness, he/she should be sent home to rest. Treatment should be postponed until the patient feels well again</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:28:29" confidence="5" anchor="- After the patient regains consciousness, he/she should be sent home to rest. T">
- ==Notify the clinical supervisor and document the seizure.==</insert>
    </audio_inserts>
  </page>
  <page number="40">
    <text>**Use the acronym to indicate the challenges regarding epilepsy in oral health care (5 mins)**

*   **Access** - The ability of someone to physically access the dental service. This also concerns timing.
*   **Communication** - What affects communicating with the person? Think about language, sensory impairments, speech difficulties, intellectual disabilities, neuro-diversity, dental fear that affect two-way communication. What do you need to communicate?
*   **Consent** - Are there difficulties in making health care decision for the person? Who is in charged?
*   **Education** - Are there specific oral health education, or preventive advice for the patient or the caregiver?
*   **Surgery** - What other adjustments should we make in the dental setting? This involves for fillings, cleaning, extraction, chair positioning etc.
*   **Spread** - Is there a cross-infectivity concern? Is the person instead at risk of infection?
*   **Oral implications** - How does the condition manifest in the mouth? What can we expect to see? This involves elements of Oral Medicine specialty.
*   **Related concerns** - What other related issues do we see with this condition. This involves effects of progression of disease, effects of medical treatment etc.</text>
    <formatted_text>Use the acronym to indicate the challenges regarding epilepsy in oral health care (5 mins).

- **Access** — The ability of someone to physically access the dental service. This also concerns timing.
- **Communication** — What affects communicating with the person? Think about language, sensory impairments, speech difficulties, intellectual disabilities, neuro-diversity, dental fear that affect two-way communication. What do you need to communicate?
- **Consent** — Are there difficulties in making health care decisions for the person? Who is in charge?
- **Education** — Are there specific oral health education, or preventive advice for the patient or the caregiver?
- **Surgery** — What other adjustments should we make in the dental setting? This involves fillings, cleaning, extraction, chair positioning etc.
- **Spread** — Is there a cross-infectivity concern? Is the person instead at risk of infection?
- **Oral implications** — How does the condition manifest in the mouth? What can we expect to see? This involves elements of Oral Medicine specialty.
- **Related concerns** — What other related issues do we see with this condition. This involves effects of progression of disease, effects of medical treatment etc.</formatted_text>
    <audio_inserts count="1">
      <insert confidence="1" anchor="- **Spread** — Is there a cross-infectivity concern? Is the person instead at ri">
- ==Infection-control concerns relate to the patient’s general health and potential transmission of infections, not epilepsy itself.==</insert>
    </audio_inserts>
  </page>
  <page number="41">
    <text>**Access**
• May require caregiver if ID or refractory epilepsy
• Variable risk of fall, refractory epilepsy
• if pt has seizure prior to appt, postpone appt
• avoid time of the day / period of time where person is prone to seizures

**Consent**
• rectal midazolam administered by OHT?
• consent issues for person with ID

**Communication**
• ask: what type, when, triggers
• anxiety can be a trigger for seizures, TLC
• remind to have light meal, medications and emergency meds
• post ictal - ask a responsible adult to escort home

**Education**
• teach family NOT to stuff anything into the mouth during seizure
• gingival hyperplasia - need v good OH, surgical removal if non-reducing</text>
    <formatted_text>#### Access

- May require caregiver if ID or refractory epilepsy
- Variable risk of fall, refractory epilepsy
- If pt has seizure prior to appt, postpone appt
- Avoid time of the day / period of time where person is prone to seizures

#### Consent

- Rectal midazolam administered by OHT?
- Consent issues for person with ID

#### Communication

- Ask: what type, when, triggers
- Anxiety can be a trigger for seizures, TLC
- Remind to have light meal, medications and emergency meds
- Post ictal — ask a responsible adult to escort home

#### Education

- Teach family NOT to stuff anything into the mouth during seizure
- Gingival hyperplasia — need very good OH, surgical removal if non-reducing</formatted_text>
  </page>
  <page number="42">
    <text>**Surgery**
• Dental emergency management of status epilepticus
• Avoid triggers - bright lights/noise/anxiety
• ill-fitting small dentures / AEB not good - risk of aspiration
• sedation with benzodiazepines may benefit. Reversal of BZD - can induce seizure
• drug interaction (aspirin azoles, metronidazole with phenytoin, carbamazepine)
• bleeding risk with valproate

**Spread**
• Epilepsy is not contagious

**Oral implications**
• worn/ground teeth: grinding tonic phase, or if fall face-first
• gingival hyperplasia - phenytoin (folate?), carbamazepine, lamotrigine, valproate
• soft tissue trauma

**Related conditions**
• Intellectual disability
• Lennox-Gaustant syndrome
• Stroke, brain trauma, brain tumors</text>
    <formatted_text>#### Surgery

- Dental emergency management of status epilepticus
- Avoid triggers — bright lights/noise/anxiety
- Ill-fitting small dentures / AEB not good — risk of aspiration
- Sedation with benzodiazepines may benefit. Reversal of BZD — can induce seizure
- Drug interaction (aspirin, azoles, metronidazole with phenytoin, carbamazepine)
- Bleeding risk with valproate

#### Spread

- Epilepsy is not contagious

#### Oral implications

- Worn/ground teeth: grinding tonic phase, or if fall face-first
- Gingival hyperplasia — phenytoin (folate?), carbamazepine, lamotrigine, valproate
- Soft tissue trauma

#### Related conditions

- Intellectual disability
- Lennox-Gaustant syndrome
- Stroke, brain trauma, brain tumors</formatted_text>
  </page>
  <page number="43">
    <text>**Multiple Sclerosis (MS)**

*   Definition.
*   Epidemiology / Background.
*   Aetiopathogenesis.
*   Clinical presentation.
*   Diagnosis / Types.
*   Treatment / Prognosis.
*   Oral findings / Side effects of medication.
*   Provision of dental treatment (ACCESS).</text>
    <formatted_text>- Definition.
- Epidemiology / Background.
- Aetiopathogenesis.
- Clinical presentation.
- Diagnosis / Types.
- Treatment / Prognosis.
- Oral findings / Side effects of medication.
- Provision of dental treatment (ACCESS).</formatted_text>
  </page>
  <page number="44">
    <text>Multiple Sclerosis (MS)

MS is the most common acquired chronic neurological disease affecting young adults, often diagnosed between the ages of 20 to 40 and, in Australia, affects three times more women than men. As yet, there is no cure. There is no known single cause of MS, but many genetic and environmental factors have been shown to contribute to its development. In MS, the body's own immune system mistakenly attacks and damages the fatty material – called myelin – around the nerves. This results in a range of symptoms, but no two people experience MS in the same way.

62%

Nearly 3m people live with MS worldwide

33.3K

$$$
$2.5bn was the estimated cost of MS to the Australian community in 2021

Average age of diagnosis is between 20-40 years

3 out of 4 Australians diagnosed with MS are women

MS affects more young adults than any other acquired chronic neurological disease

131 Australians living with MS per 100k people, up from 103 in 2017

MS RESEARCH ADVOCACY CURE AUSTRALIA

![62% of people with MS use a disease modifying therapy (DMT), a decrease of 2% since 2017](L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_e9cd0d484ebc2678.webp)
![More than 33K Australians live with MS](L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_7c077f73d37efa02.webp)</text>
    <formatted_text>MS is the most common acquired chronic neurological disease affecting young adults, often diagnosed between the ages of 20 to 40 and, in Australia, affects three times more women than men. As yet, there is no cure. There is no known single cause of MS, but many genetic and environmental factors have been shown to contribute to its development. In MS, the body's own immune system mistakenly attacks and damages the fatty material – called myelin – around the nerves. This results in a range of symptoms, but no two people experience MS in the same way.

#### Key Statistics

- **62%** — nearly 3 million people live with MS worldwide.
- **$2.5bn** was the estimated cost of MS to the Australian community in 2021.
- Average age of diagnosis is between 20–40 years.
- 3 out of 4 Australians diagnosed with MS are women.
- MS affects more young adults than any other acquired chronic neurological disease.
- 131 Australians living with MS per 100,000 people, up from 103 in 2017.</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:35:28" confidence="3" anchor="131 Australians living with MS per 100,000 people, up from 103 in 2017.">
- ==Approximately 33,000 Australians have multiple sclerosis, representing about 0.131% of the population.==</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="99,451,174,553" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="chart" path="L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_e9cd0d484ebc2678.webp" caption="62% of people with MS use a disease modifying therapy (DMT), a decrease of 2% since 2017">
        <description>A donut chart with a thick red ring representing 62% of the circle, labeled '62%' in the center white space. The remaining portion of the ring is light pink.</description>
      </img>
      <img order="1" bbox="588,450,669,552" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="figure" path="L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_7c077f73d37efa02.webp" caption="More than 33K Australians live with MS">
        <description>A red silhouette map of Australia containing the white text '33.3K', illustrating the number of people living with Multiple Sclerosis in the country.</description>
      </img>
    </images>
  </page>
  <page number="45">
    <text>Definition

• Chronic relapsing demyelinating CNS disease.
• Cause sensory, motor and psychological symptoms.
• Characterised by the formation of plaques throughout the CNS.

Multiple Sclerosis: Damaged Myelin

Nerve cell
Myelin
Nerve fiber
Signal from brain
Muscle fiber

Nerve cell
Myelin
Damaged myelin (plaques)
Nerve fiber
Signal from brain
Muscle fiber

Psych 256: Cognitive Psychology SP15.&quot; Psych 256 Cognitive Psychology SP15. Web. 28 Oct. 2015.

![Normal](L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_bfb8f0afffbe0afb.webp)
![Multiple Sclerosis: Damaged Mylin](L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_b04c6a2240dc92d3.webp)</text>
    <formatted_text>#### Definition

- Chronic relapsing demyelinating CNS disease.
- Causes sensory, motor and psychological symptoms.
- Characterised by the formation of plaques throughout the CNS.

#### Multiple Sclerosis: Damaged Myelin

- Healthy myelin: nerve cell → myelin → nerve fiber → signal from brain → muscle fiber.
- Damaged myelin: nerve cell → damaged myelin (plaques) → nerve fiber → signal from brain → muscle fiber.

*Psych 256: Cognitive Psychology SP15. Web. 28 Oct. 2015.*</formatted_text>
    <images>
      <img order="0" bbox="654,372,812,720" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="diagram" path="L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_bfb8f0afffbe0afb.webp" caption="Normal">
        <description>This labelled diagram illustrates the structure of a normal neuron and its connection to a muscle fiber. It depicts the nerve cell body extending an axon sheathed in myelin, with a black arrow indicating the direction of the 'Signal from brain' traveling down the nerve fiber to reach the muscle.</description>
      </img>
      <img order="1" bbox="652,361,979,727" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="diagram" path="L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_b04c6a2240dc92d3.webp" caption="Multiple Sclerosis: Damaged Mylin">
        <description>A labelled schematic diagram comparing a normal nerve cell with one affected by Multiple Sclerosis, illustrating the damage to myelin sheaths. The image displays two side-by-side neurons connected to muscle fibers, where the right-hand example shows 'Damaged myelin (plaques)' disrupting the smooth transmission of signals from the brain.</description>
      </img>
    </images>
  </page>
  <page number="46">
    <text>**Background**

• The two common symptoms are pain and spasticity (stiff and spasm).

• Disease progression: muscle spasm, immobility, disturbed sleep, pain and fatigue occur.</text>
    <formatted_text>#### Background

- The two common symptoms are pain and spasticity (stiff and spasm).
- Disease progression: muscle spasm, immobility, disturbed sleep, pain and fatigue occur.</formatted_text>
  </page>
  <page number="47">
    <text>**Aetiopathogenesis**

*   Unclear.
*   Maybe familial predisposition.
*   Maybe autoimmune in genetically susceptible individuals perhaps viral aetiology (HHV 6).
*   Sunlight exposure appears to reduce risk</text>
    <formatted_text>- Unclear.
- Maybe familial predisposition.
- Maybe autoimmune in genetically susceptible individuals, perhaps viral aetiology (HHV 6).
- Sunlight exposure appears to reduce risk.</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:37:57" confidence="4" anchor="- Sunlight exposure appears to reduce risk.">

&gt; [!note] Lecturer — Sunlight and Disease Activity
&gt; Geographical and sunlight-related factors may influence multiple sclerosis prevalence.
&gt;
&gt; - Areas with less sunlight were described as having a higher prevalence.
&gt; - Disease activity relates to an overactive immune system attacking myelin.
</insert>
    </audio_inserts>
  </page>
  <page number="48">
    <text>Clinical presentation

Main symptoms of
Multiple sclerosis

**Central:**
- Fatigue
- Cognitive impairment
- Depression
- Unstable mood

**Visual:**
- Nystagmus
- Optic neuritis
- Diplopia

**Speech:**
- Dysarthria

**Throat:**
- Dysphagia

**Musculoskeletal:**
- Weakness
- Spasms
- Ataxia

**Sensation:**
- Pain
- Hypoesthesias
- Paraesthesias

**Bowel:**
- Incontinence
- Diarrhea or constipation

**Urinary:**
- Incontinence
- Frequency or retention

48 New Genetic Variants Linked to Multiple Sclerosis.&quot; 48 New Genetic Variants Linked to Multiple Sclerosis. Web. 28 Oct. 2015..</text>
    <formatted_text>#### Main Symptoms of Multiple Sclerosis

- **Central:** fatigue, cognitive impairment, depression, unstable mood.
- **Visual:** nystagmus, optic neuritis, diplopia.
- **Speech:** dysarthria.
- **Throat:** dysphagia.
- **Musculoskeletal:** weakness, spasms, ataxia.
- **Sensation:** pain, hypoesthesias, paraesthesias.
- **Bowel:** incontinence, diarrhea or constipation.
- **Urinary:** incontinence, frequency or retention.

*&quot;48 New Genetic Variants Linked to Multiple Sclerosis.&quot; Web. 28 Oct. 2015.*</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:38:22" confidence="6" anchor="- **Urinary:** incontinence, frequency or retention.">
- ==Cognitive impairment usually occurs at later stages, while optic neuritis may be unilateral and accompanied by rapid visual deterioration.==</insert>
    </audio_inserts>
  </page>
  <page number="49">
    <text>**Diagnosis**

*   Clinical findings during acute attacks.
*   MRI.
*   Delayed visual evoked response potentials (VEPs).
*   Lumbar puncture - CSF examination: shows increased IgG and slightly increased WBC.</text>
    <formatted_text>#### Diagnosis

- Clinical findings during acute attacks.
- MRI.
- Delayed visual evoked response potentials (VEPs).
- Lumbar puncture – CSF examination: shows increased IgG and slightly increased WBC.</formatted_text>
  </page>
  <page number="50">
    <text>**Types**

• Varies in severity and speed of evolution.
• Classified based on clinical course to:
1. Relapsing – remitting.
2. Primary progressive.
3. Secondary progressive.
4. Progressive relapsing.</text>
    <formatted_text>#### Types

- Varies in severity and speed of evolution.
- Classified based on clinical course to:

1. Relapsing – remitting.
2. Primary progressive.
3. Secondary progressive.
4. Progressive relapsing.</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:39:55" confidence="3" anchor="4. Progressive relapsing.">
- ==Relapsing-remitting disease has symptom-free periods after improvement, whereas primary progressive disease advances without remission phases; secondary progressive disease may follow an earlier relapsing-remitting course.==</insert>
    </audio_inserts>
  </page>
  <page number="51">
    <text>**Treatment**

*   Multidisciplinary team.
*   No effective reliable treatment for MS.
*   Disease modifying agents (DMAs) – beta interferons and glatiramer (Immunomodulator).
*   Corticosteroids for acute episodes.
*   Anti-inflammatory agents like natalizumab.
*   SYMPTOMATIC MANAGEMENT - Muscle relaxant (Tizanidine).</text>
    <formatted_text>#### Treatment

- Multidisciplinary team.
- No effective reliable treatment for MS.
- Disease modifying agents (DMAs) – beta interferons and glatiramer (immunomodulator).
- Corticosteroids for acute episodes.
- Anti-inflammatory agents like natalizumab.
- Symptomatic management – muscle relaxant (Tizanidine).</formatted_text>
  </page>
  <page number="52">
    <text>**Prognosis**

• Most patient survive at least 20-30 years.
• After 25 years more than 75% of patients are still alive.
• Remission, complete, and partial are common.
• Fulminant MS (or malignant) occur occasionally and progress rapidly.</text>
    <formatted_text>#### Prognosis

- Most patients survive at least 20–30 years.
- After 25 years more than 75% of patients are still alive.
- Remission, complete and partial, are common.
- Fulminant MS (or malignant) occurs occasionally and progresses rapidly.</formatted_text>
  </page>
  <page number="53">
    <text>**Oral findings**

• No specific oral manifestation.

• But consider diagnosis in suspected clinical presentations, such as

• young patient with bilateral trigeminal neuralgia

• facial palsy but unlike Bell’s palsy (e.g. without retroaural pain)</text>
    <formatted_text>#### Oral Findings

- No specific oral manifestation.
- But consider diagnosis in suspected clinical presentations, such as:
  - A young patient with bilateral trigeminal neuralgia.
  - Facial palsy but unlike Bell's palsy (e.g. without retroaural pain).</formatted_text>
  </page>
  <page number="54">
    <text>**Oral side effect of medication**

• Dry mouth due to:
– Atropine used in treating the bladder dysfunction.
– Tizanidine (muscle relaxant).
• Long-term steroid use
• Facial oedema caused by glatiramer (immunomodulator).</text>
    <formatted_text>#### Oral Side Effects of Medication

- Dry mouth due to:
  - Atropine used in treating the bladder dysfunction.
  - Tizanidine (muscle relaxant).
- Long-term steroid use.
- Facial oedema caused by glatiramer (immunomodulator).</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:43:02" confidence="5" anchor="- Facial oedema caused by glatiramer (immunomodulator).">
- ==Atropine and antimuscarinic muscle relaxants can reduce salivary flow, causing dry mouth and increased caries risk.==
- ==Long-term steroid use should be considered when planning surgical procedures, including the possible need for steroid cover.==</insert>
    </audio_inserts>
  </page>
  <page number="55">
    <text>**References**

*   MS Australia. https://www.msaustralia.org.au/what-is-multiple-sclerosis-ms/
*   National Multiple Sclerosis Society. Web. 28 Oct. 2015.
*   Psych 256: Cognitive Psychology SP15.&quot; Psych 256 Cognitive Psychology SP15. Web. 28 Oct. 2015.
*   Scully, Crispian. *Scully's Medical Problems in Dentistry*. Elsevier Health Sciences, 2014.
*   Scully, Crispian, Pedro Diz Dios, and Navdeep Kumar. *Special care in dentistry: Handbook of oral healthcare*. Elsevier Health Sciences, 2006.
*   48 New Genetic Variants Linked to Multiple Sclerosis.&quot; 48 New Genetic Variants Linked to Multiple Sclerosis. Web. 28 Oct. 2015.</text>
    <formatted_text>#### References

- MS Australia. https://www.msaustralia.org.au/what-is-multiple-sclerosis-ms/
- National Multiple Sclerosis Society. Web. 28 Oct. 2015.
- *Psych 256: Cognitive Psychology SP15. Web. 28 Oct. 2015.*
- *Scully, Crispian. Scully's Medical Problems in Dentistry. Elsevier Health Sciences, 2014.*
- *Scully, Crispian, Pedro Diz Dios, and Navdeep Kumar. Special care in dentistry: Handbook of oral healthcare. Elsevier Health Sciences, 2006.*
- *&quot;48 New Genetic Variants Linked to Multiple Sclerosis.&quot; Web. 28 Oct. 2015.*</formatted_text>
  </page>
  <page number="56">
    <text/>
  </page>
  <page number="57">
    <text>Parkinson’s Disease

Classical Features

*   Tremors (Dyskinesia)
*   Rigidity (Akinesia)
*   Slowness (Bradykinesia)
*   Postural instability and gait disturbances

(Jankovic, 2007; Gallagher, 2013; Schneider &amp; Obeso, 2015)

4GIFs.com

Stooped posture
Masked facial expression
Rigidity
Forward tilt of trunk
Flexed elbows &amp; wrists
Reduced arm swinging
Slightly flexed hips &amp; knees
Trembling of extremities
Shuffling, short-stepped gait
© UWorld

![Camera stabilizing tech used in spoon for Parkinson's](L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_440919ba849f0a6f.webp)
![](L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_b68cd5d5038af843.webp)</text>
    <formatted_text>#### Classical Features

- Tremors (Dyskinesia)
- Rigidity (Akinesia)
- Slowness (Bradykinesia)
- Postural instability and gait disturbances

*(Jankovic, 2007; Gallagher, 2013; Schneider &amp; Obeso, 2015)*

#### Physical Signs

- Stooped posture
- Masked facial expression
- Rigidity
- Forward tilt of trunk
- Flexed elbows &amp; wrists
- Reduced arm swinging
- Slightly flexed hips &amp; knees
- Trembling of extremities
- Shuffling, short-stepped gait

*(© UWorld)*</formatted_text>
    <audio_inserts count="2">
      <insert timestamp="00:43:57" confidence="7" anchor="- Postural instability and gait disturbances">

&gt; [!note] Lecturer — Disease Mechanism
&gt; Parkinson's disease is a progressive neurodegenerative disease traditionally considered a movement disorder. It is thought to involve degeneration of dopaminergic neurons in the substantia nigra.
</insert>
      <insert timestamp="01:10:31" confidence="4" anchor="- Shuffling, short-stepped gait">
&gt; - ==Tremors and involuntary movements may affect radiographic procedures, and advanced hunched posture may prevent an OPG machine from passing evenly across the back.==</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="269,292,602,836" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_440919ba849f0a6f.webp" caption="Camera stabilizing tech used in spoon for Parkinson's">
        <description>This is a photograph (likely a still from a video) showing an elderly man holding a specialized eating utensil, identified by the caption as camera stabilizing technology used in a spoon for Parkinson's patients. The image illustrates the device being used to eat from a bowl.</description>
      </img>
      <img order="1" bbox="609,313,965,923" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="figure" path="L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_b68cd5d5038af843.webp">
        <description>Labelled diagram of a male patient illustrating the classical motor features of Parkinson's disease. The text annotations identify specific clinical signs: Stooped posture, Rigidity, Flexed elbows &amp; wrists, Trembling of extremities, Masked facial expression, Forward tilt of trunk, Reduced arm swinging, Slightly flexed hips &amp; knees, and Shuffling, short-stepped gait.</description>
      </img>
    </images>
  </page>
  <page number="58">
    <text>Parkinson’s Disease

Non-motor symptoms
Sensory disturbances
Autonomic dysfunctions
Neurological deficits
Sleep disturbances

(depression, sleep disorders, weight loss,)
(forced closure of the eyelids [blepharospasm])
(orthostatic hypotension)
(constipation, micturition disorders, sexual problems,)
(increased sweating)
(difficulty speaking, excessive salivation, difficulty in swallowing, respiratory problems,)
(bowing of the shoulders, swelling of the feet,)

(Quinn et al., 1987; Jankovic, 2007; Gallagher, 2013; Schneider &amp; Obeso, 2015)

![Parkinson's Disease Non-motor symptoms](L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_efba79012357371d.webp)</text>
    <formatted_text>#### Non-Motor Symptoms

- Sensory disturbances
- Autonomic dysfunctions
- Neurological deficits
- Sleep disturbances

Associated features include:

- depression, sleep disorders, weight loss
- forced closure of the eyelids (blepharospasm)
- orthostatic hypotension
- constipation, micturition disorders, sexual problems
- increased sweating
- difficulty speaking, excessive salivation, difficulty in swallowing, respiratory problems
- bowing of the shoulders, swelling of the feet

*(Quinn et al., 1987; Jankovic, 2007; Gallagher, 2013; Schneider &amp; Obeso, 2015)*</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:45:21" confidence="4" anchor="*(Quinn et al., 1987; Jankovic, 2007; Gallagher, 2013; Schneider &amp; Obeso, 2015)*">

&gt; [!note] Lecturer — Early Symptoms
&gt; Some sensory and sleep symptoms may occur 20 to 30 years before diagnosis. Cognitive changes, dysphagia and dementia may occur at later stages.
</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="55,213,498,855" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="figure" path="L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_efba79012357371d.webp" caption="Parkinson's Disease Non-motor symptoms">
        <description>A schematic diagram illustrating various non-motor symptoms of Parkinson's Disease, featuring a central human silhouette connected by lines to circular insets depicting affected body parts and conditions. The labelled illustrations include a brain for depression and sleep disorders, eyes for blepharospasm, the heart for orthostatic hypotension, intestines for constipation, lungs for respiratory problems, skin for sweating, and a posture figure for bowing shoulders.</description>
      </img>
    </images>
  </page>
  <page number="59">
    <text>Diagnosis

**UK Parkinson’s disease Society Brain Bank criteria:**

Step 1. Diagnosis of Parkinson Syndrome
- Bradykinesia
- At least one of the following:
• Muscular rigidity
• 4-6 Hz rest tremor
• Postural instability

Step 2. Exclusion of other similar diseases and mimicking signs

Step 3. Three or more supportive characteristics

**Hughes et al., 1992**</text>
    <formatted_text>#### UK Parkinson's Disease Society Brain Bank Criteria

**Step 1 — Diagnosis of Parkinson Syndrome**

- Bradykinesia
- At least one of the following:
  - Muscular rigidity
  - 4–6 Hz rest tremor
  - Postural instability

**Step 2 — Exclusion of other similar diseases and mimicking signs**

**Step 3 — Three or more supportive characteristics**

*(Hughes et al., 1992)*</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:47:17" confidence="3" anchor="*(Hughes et al., 1992)*">

&gt; [!note] Lecturer — Idiopathic Disease
&gt; Parkinson's disease is described as idiopathic when it is not caused by another condition or medication.
</insert>
    </audio_inserts>
  </page>
  <page number="60">
    <text>Diagnosis

Five stages of PD: Hoehn &amp; Yahr Scale

| Stage | Symptoms |
| :--- | :--- |
| I (Mild – Early disease) | There is no to minimal functional impairment. Only one side of the body is affected. |
| II | Posture and balance are normal even though both sides of the body are affected. |
| III (Moderate) | Mild imbalance when standing or walking, both sides of the body are affected but the patient is independent. |
| IV (Severe – Advanced disease) | Imbalance when standing or walking is disabling, both sides of the body are affected and the patient requires assistance. |
| V | The patient is cachectic, restricted to bed or wheelchair and needs complete assistance for daily living activities. |

Hoehn &amp; Yahr; Braak et al., 2003; Hughes et al., 1992

![Braak staging](L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_e83e61b1ec05e23c.webp)</text>
    <formatted_text>#### Five Stages of PD: Hoehn &amp; Yahr Scale

| Stage | Symptoms |
| :--- | :--- |
| I (Mild – Early disease) | There is no to minimal functional impairment. Only one side of the body is affected. |
| II | Posture and balance are normal even though both sides of the body are affected. |
| III (Moderate) | Mild imbalance when standing or walking, both sides of the body are affected but the patient is independent. |
| IV (Severe – Advanced disease) | Imbalance when standing or walking is disabling, both sides of the body are affected and the patient requires assistance. |
| V | The patient is cachectic, restricted to bed or wheelchair and needs complete assistance for daily living activities. |

*(Hoehn &amp; Yahr; Braak et al., 2003; Hughes et al., 1992)*</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:48:02" confidence="4" anchor="*(Hoehn &amp; Yahr; Braak et al., 2003; Hughes et al., 1992)*">

&gt; [!note] Lecturer — Braak Staging
&gt; Braak staging is histopathological and generally cannot be diagnosed during life. It involves examining the brain after death and assessing the distribution of misfolded proteins as the disease progresses through the brain stem and other brain regions.
</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="655,316,990,637" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="diagram" path="L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_e83e61b1ec05e23c.webp" caption="Braak staging">
        <description>A schematic sagittal view of the human brain illustrating the progression of pathology, indicated by red shading that originates in the lower brainstem and spreads upward into the midbrain, limbic structures, and finally the neocortex. White arrows trace this ascending pathway from the medulla through the pons and substantia nigra towards the temporal lobe and frontal cortex.</description>
      </img>
    </images>
  </page>
  <page number="61">
    <text>Prevalence of Parkinson’s Disease

2005
100% = 4.1 million individuals
Others, 12%
Brazil, 4%
U.S. 8%
India, 8%
Europe, 20%
China, 48%

2030
100% = 8.7 million individuals
Others, 10%
Brazil, 4%
U.S. 7%
India, 8%
Europe, 14%
China, 57%

**Worldwide:**
• Worldwide, 1 in every 3000
• 6.3 million worldwide (2016)
• 8.7-9.3 million worldwide by 2030
• 1 in 500 people in “W.E.I.R.D” countries

**Ratio in genders:**
• Male to female ratio of 1.46

Dorsey et al., 2007; Parkinson’s UK; Parkinson’s Singapore; PSGP; Pringsheim et al., 2014; Taylor et al., 2007

![*Among individuals over 50 in the world’s ten most and Western Europe’s five most populous nations](L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_6fe0e6c9b61e8826.webp)</text>
    <formatted_text>#### Prevalence of Parkinson's Disease

**2005** — 100% = 4.1 million individuals

- China, 48%
- Europe, 20%
- India, 8%
- U.S., 8%
- Brazil, 4%
- Others, 12%

**2030** — 100% = 8.7 million individuals

- China, 57%
- Europe, 14%
- India, 8%
- U.S., 7%
- Brazil, 4%
- Others, 10%

#### Worldwide Figures

- Worldwide, 1 in every 3000
- 6.3 million worldwide (2016)
- 8.7–9.3 million worldwide by 2030
- 1 in 500 people in &quot;W.E.I.R.D&quot; countries

#### Ratio in Genders

- Male to female ratio of 1.46

*(Dorsey et al., 2007; Parkinson's UK; Parkinson's Singapore; PSGP; Pringsheim et al., 2014; Taylor et al., 2007)*</formatted_text>
    <images>
      <img order="0" bbox="219,243,785,534" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="chart" path="L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_6fe0e6c9b61e8826.webp" caption="*Among individuals over 50 in the world’s ten most and Western Europe’s five most populous nations">
        <description>Two pie charts illustrating the projected prevalence of Parkinson's Disease in 2005 and 2030, broken down by country or region. The segments are visually represented by national flags (China, European Union, India, USA, Brazil) and labeled with their respective percentage shares.</description>
      </img>
    </images>
  </page>
  <page number="62">
    <text>Risk factors

❖ Age
 Genetics (OR: 4.19)
   • SNCA, LRRK2, PARK2, PINK, PARK etc.
❖ Toxins exposure (OR: 3.09)
   • Pesticides (paraquat, rotenone &amp; maneb)
   • Herbicides, insecticides, metals etc.
❖ Trauma to the head (OR: 1.57)
   • Boxing, Muay Thai etc.

2000
1500
1000
500
0
40-49
50-59
60-69
70-79
80+

Irwin et al., 2012; Jenner et al., 2013; Jafari et al., 2013; Wang et al., 2011; Li et al., 2015; Hernán et al., 2002; Tan et al., 2008

![Age Prevalence of Parkinson’s Disease](L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_bf159b9fd783d110.webp)</text>
    <formatted_text>#### Risk Factors

- **Age** — prevalence increases with age (40–49, 50–59, 60–69, 70–79, 80+)
- **Genetics** (OR: 4.19)
  - SNCA, LRRK2, PARK2, PINK, PARK etc.
- **Toxins exposure** (OR: 3.09)
  - Pesticides (paraquat, rotenone &amp; maneb)
  - Herbicides, insecticides, metals etc.
- **Trauma to the head** (OR: 1.57)
  - Boxing, Muay Thai etc.

*(Irwin et al., 2012; Jenner et al., 2013; Jafari et al., 2013; Wang et al., 2011; Li et al., 2015; Hernán et al., 2002; Tan et al., 2008)*</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:49:38" confidence="5" anchor="*(Irwin et al., 2012; Jenner et al., 2013; Jafari et al., 2013; Wang et al., 201">
&gt; - ==Muhammad Ali and Michael J. Fox were mentioned as people who developed Parkinson's disease at relatively young ages.==</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="539,339,995,876" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="chart" path="L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_bf159b9fd783d110.webp" caption="Age Prevalence of Parkinson’s Disease">
        <description>A 3D bar chart showing a sharp increase in values across age groups labeled on the x-axis from '40-49' to '80+', with a y-axis scale ranging from 0 to 2000. The chart is overlaid on a background image of a boxer wearing gloves.</description>
      </img>
    </images>
  </page>
  <page number="63">
    <text>Protective factors

✤ Smoking (RR: 0.59)
✤ Coffee (RR: 0.69)
✤ Black tea (RR: 0.28)

Irwin et al., 2012; Jenner et al., 2013; Jafari et al., 2013; Wang et al., 2011; Li et al., 2015; Hernán et al., 2002; Tan et al., 2008; Barreto et al., 2015

![](L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_af4c3812535e3bd3.webp)</text>
    <formatted_text>#### Protective Factors

- Smoking (RR: 0.59)
- Coffee (RR: 0.69)
- Black tea (RR: 0.28)

*(Irwin et al., 2012; Jenner et al., 2013; Jafari et al., 2013; Wang et al., 2011; Li et al., 2015; Hernán et al., 2002; Tan et al., 2008; Barreto et al., 2015)*</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:50:45" confidence="5" anchor="- Black tea (RR: 0.28)">

&gt; [!note] Lecturer — Protective Mechanisms
&gt; Nicotine was suggested as a possible compound involved in the association between smoking and reduced Parkinson's disease risk. Proposed effects included reduced neuroinflammation and improved survival of dopaminergic neurons; caffeine was described as stimulating additional dopamine production.
</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="510,545,928,914" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_af4c3812535e3bd3.webp">
        <description>A close-up photograph of an elderly person's hands resting on a wooden cane handle, holding a lit cigarette.</description>
      </img>
    </images>
  </page>
  <page number="64">
    <text># Pharmacological management

• Levodopa and combinations
(duodopa, carbidopa)

• MAO-B inhibitor (selegiline,
rasagline, safinamide)

• COMT inhibitors (entacapone,
tolcapone)

• Dopamine agonist (pramipexole,
ropinirole, apomorphine)

• Anticholinergics (trihexyphenidyl,
benztropine)

• Others: propranolol, amantadine,
clozapine, rivastigmine

http://www.azilect.com/AboutParkinsonsDisease/ParkinsonsTreatment

![How PD Medications Work](L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_7fbec835bbc4bce2.webp)</text>
    <formatted_text>#### Pharmacological Management

- Levodopa and combinations (duodopa, carbidopa)
- MAO-B inhibitor (selegiline, rasagiline, safinamide)
- COMT inhibitors (entacapone, tolcapone)
- Dopamine agonist (pramipexole, ropinirole, apomorphine)
- Anticholinergics (trihexyphenidyl, benztropine)
- Others: propranolol, amantadine, clozapine, rivastigmine</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:51:50" confidence="5" anchor="- Others: propranolol, amantadine, clozapine, rivastigmine">

&gt; [!note] Lecturer — Medication Mechanisms
&gt; Pharmacological management aims to increase dopamine availability. Monoamine oxidase B inhibitors reduce dopamine breakdown in the brain, while catechol-O-methyltransferase inhibitors reduce peripheral degradation of levodopa; anticholinergic drugs can cause significant oral dryness.
</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="46,361,554,896" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="diagram" path="L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_7fbec835bbc4bce2.webp" caption="How PD Medications Work">
        <description>This schematic illustrates the mechanism of action for various Parkinson's disease medications at a synapse involving a dopamine-producing neuron. It depicts a blood-brain barrier and uses colored icons to show how Levodopa (blue circle 'L') crosses into the neuron, Dopamine (pink circle 'D') is released, Dopamine-agonists (blue oval 'DA') bind to receptors, and MAO-B inhibitors (purple square 'I') block reuptake. Text boxes explicitly state that COMT inhibitors preserve levodopa, Levodopa replaces dopamine, Dopamine agonists mimic dopamine, and MAO-B inhibitors preserve existing dopamine.</description>
      </img>
    </images>
  </page>
  <page number="65">
    <text>Surgical or Therapy

**Supportive therapies:**
• Physical and strength therapy
• Speech and Language Therapy
• Occupational Therapy

**Surgical interventions:**
• Deep brain stimulation
• Lesioning

(NICE [IPG19] 2003; Metman &amp; Salvin, 2015; Poortvliet et al., 2015; Young et al., 1998; Dwarakanath et al., 2014; Tomlinson et al., 2013; Cruickshank et al., 2015; NICE [CG35], 2006; Smith et al., 2012)</text>
    <formatted_text>#### Surgical or Therapy

**Supportive therapies:**

- Physical and strength therapy
- Speech and Language Therapy
- Occupational Therapy

**Surgical interventions:**

- Deep brain stimulation
- Lesioning

*(NICE [IPG19] 2003; Metman &amp; Salvin, 2015; Poortvliet et al., 2015; Young et al., 1998; Dwarakanath et al., 2014; Tomlinson et al., 2013; Cruickshank et al., 2015; NICE [CG35], 2006; Smith et al., 2012)*</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:53:56" confidence="4" anchor="*(NICE [IPG19] 2003; Metman &amp; Salvin, 2015; Poortvliet et al., 2015; Young et al">

&gt; [!note] Lecturer — Surgical Options
&gt; Deep brain stimulation is useful for some subtypes but not all. Lesioning removes part of the brain to reduce tremor but may result in loss of other functions, so it is performed less often today.
</insert>
    </audio_inserts>
  </page>
  <page number="66">
    <text>### Implications on Oral Health Care

**Access**
- physical ability to access service
- appointment matters

**Communication**
- between patient - dentist
- caregivers, and dental team
- language
- sensory impairments

**Education**
- specialised OHI
- carers and family
- health advice

**Consent**
- ethical-legal concern
- mental capacity

**Surgery**
- concerns in dental surgery
- drug reactions
- emergencies

**Spread**
- cross-infectivity
- progression of disease

**Oral manifestations**
- tissue changes
- xerostomia

**Related conditions**
- similar conditions
- falls, dysphagia, dementia</text>
    <formatted_text>#### Implications on Oral Health Care

- **Access**
  - physical ability to access service
  - appointment matters
- **Communication**
  - between patient – dentist
  - caregivers, and dental team
  - language
  - sensory impairments
- **Education**
  - specialised OHI
  - carers and family
  - health advice
- **Consent**
  - ethical-legal concern
  - mental capacity
- **Surgery**
  - concerns in dental surgery
  - drug reactions
  - emergencies
- **Spread**
  - cross-infectivity
  - progression of disease
- **Oral manifestations**
  - tissue changes
  - xerostomia
- **Related conditions**
  - similar conditions
  - falls, dysphagia, dementia</formatted_text>
    <audio_inserts count="3">
      <insert timestamp="00:54:26" confidence="5" anchor="- **Access**   - physical ability to access service   - appointment matters">

&gt; [!note] Lecturer — Appointment Timing
&gt; Patients may function better earlier in the day. Appointments should therefore be planned accordingly.
</insert>
      <insert timestamp="00:56:07" confidence="4" anchor="- tissue changes   - xerostomia">
    &gt; - ==Patients may need specialised oral hygiene tools, and caregivers may need instruction in oral hygiene.==</insert>
      <insert timestamp="00:55:28" confidence="4" anchor="- **Related conditions**   - similar conditions   - falls, dysphagia, dementia">

&gt; [!note] Lecturer — Communication Barriers
&gt; Communication may be difficult because of rigidity, difficulty speaking, hearing problems, cognitive changes or reversion to a primary language. Caregivers may assist with communication and treatment.
</insert>
    </audio_inserts>
  </page>
  <page number="67">
    <text># Surgery</text>
    <formatted_text>*Surgery*</formatted_text>
  </page>
  <page number="68">
    <text># Surgery

*   Pain and Anxiety Control
*   General Anaesthesia Considerations
*   Drug Reactions
*   Dysphagia
*   Deep Brain Stimulation

Outreach Tacloban

![Dental surgery outreach team performing a procedure](L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_cf94ef1166c9634e.webp)</text>
    <formatted_text>#### Surgery

- Pain and Anxiety Control
- General Anaesthesia Considerations
- Drug Reactions
- Dysphagia
- Deep Brain Stimulation</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:58:51" confidence="5" anchor="- Deep Brain Stimulation">

&gt; [!note] Lecturer — Anaesthesia Risks
&gt; Elderly patients with Parkinson's disease may not tolerate general anaesthesia well. Low-dose sedation may be sufficient for some procedures, while general anaesthesia involves increased risks for elderly patients.
</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="500,0,1000,994" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_cf94ef1166c9634e.webp" caption="Dental surgery outreach team performing a procedure">
        <description>Clinical photo: Two dental professionals wearing scrubs, masks, and headlamps are performing a procedure on a seated patient. A portable dental kit with instruments and a suction unit is set up in the foreground.</description>
      </img>
    </images>
  </page>
  <page number="69">
    <text>Surgery
Pain and Anxiety

Local anaesthesia
• generally safe
• recommendations to limit to 3 cartridges

Sedation
• Midazolam can be effective
• Nitrous Oxide good for tremors
• Tolerance can be induced
• Propofol and Ketamine concerns

(Nicholson et al., 2002; Burton, 2004; Shimohata et al., 2015; Chen &amp; Wilkinson, 2012; Peretz et al., 2005; Gerlach et al., 2011; Golden et al., 1989)

![](L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_ea53014e7a09df65.webp)</text>
    <formatted_text>#### Pain and Anxiety Control

**Local anaesthesia**

- generally safe
- recommendations to limit to 3 cartridges

**Sedation**

- Midazolam can be effective
- Nitrous Oxide good for tremors
- Tolerance can be induced
- Propofol and Ketamine concerns

*(Nicholson et al., 2002; Burton, 2004; Shimohata et al., 2015; Chen &amp; Wilkinson, 2012; Peretz et al., 2005; Gerlach et al., 2011; Golden et al., 1989)*</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="01:17:02" confidence="2" anchor="*(Nicholson et al., 2002; Burton, 2004; Shimohata et al., 2015; Chen &amp; Wilkinson">
&gt; - ==The level of sedation should be carefully considered in older patients.==</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="0,269,512,878" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_ea53014e7a09df65.webp">
        <description>Clinical photo showing a dentist or hygienist in blue scrubs and gloves examining an older male patient seated in a dental chair. The patient is smiling slightly while looking toward the clinician, illustrating a calm clinical interaction relevant to pain and anxiety management.</description>
      </img>
    </images>
  </page>
  <page number="70">
    <text>Surgery
Drug Prescription

| Prescribing Drug | Interacting Drug | Can cause | Management options |
| :--- | :--- | :--- | :--- |
| **Opioids** | • *SSRI*&lt;br&gt;• *Deep Brain Stimulation*&lt;br&gt;• *MAO-B inhibitor (selegiline, rasagline, safinamide)* | *Hyperstimulation*&lt;br&gt;*Serotonin syndrome* | *Avoid use of opioids.*&lt;br&gt;*Consider NSAIDS or Paracetamol* |
| **NSAIDS** | • $\beta$ blockers (*proponalol, atenolol*) | *Hypotensive effects of $\beta$ blockers reduced* | *Use with caution.* |
| **NSAIDS** | • *SSRI (citalopram, fluoxetine, sertraline)* | *Risk of gastric bleeding* | *Use with caution.* |
| **NSAIDS** | • *COMT inhibitors (entacapone, tolcapone)* | *Hyperstimulation* | *Avoid use if possible. Paracetamol, otherwise consult doctor.* |

(Starr, 1991; El-Okdi et al., 2014; Greenier et al., 2015; Shakoor et al., 2014; BNF, 2016; Dawoud et al., 2014)

![](L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_a6f1d5e3cac36cfd.webp)</text>
    <formatted_text>#### Drug Prescription

| Prescribing Drug | Interacting Drug | Can cause | Management options |
| :--- | :--- | :--- | :--- |
| Opioids | SSRI; Deep Brain Stimulation; MAO-B inhibitor (selegiline, rasagiline, safinamide) | Hyperstimulation; Serotonin syndrome | Avoid use of opioids. Consider NSAIDS or Paracetamol |
| NSAIDS | β blockers (propranolol, atenolol) | Hypotensive effects of β blockers reduced | Use with caution. |
| NSAIDS | SSRI (citalopram, fluoxetine, sertraline) | Risk of gastric bleeding | Use with caution. |
| NSAIDS | COMT inhibitors (entacapone, tolcapone) | Hyperstimulation | Avoid use if possible. Paracetamol, otherwise consult doctor. |

*(Starr, 1991; El-Okdi et al., 2014; Greenier et al., 2015; Shakoor et al., 2014; BNF, 2016; Dawoud et al., 2014)*</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:59:46" confidence="4" anchor="*(Starr, 1991; El-Okdi et al., 2014; Greenier et al., 2015; Shakoor et al., 2014">

&gt; [!note] Lecturer — Analgesic Selection
&gt; Tramadol may interact with other drugs and cause serotonin syndrome. Opioids are generally avoided in older patients because of their sedative effects, and paracetamol was described as a generally safer first-line analgesic.
</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="72,275,937,849" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_a6f1d5e3cac36cfd.webp">
        <description>A four-column table detailing drug interactions, listing the prescribing drug (Opioids, NSAIDS), interacting drugs (e.g., SSRI, MAO-B inhibitors, beta blockers), potential adverse effects (e.g., serotonin syndrome, gastric bleeding), and management options.</description>
      </img>
    </images>
  </page>
  <page number="71">
    <text>Electrode
Subthalamic nucleus (STN)
Extension lead
Neurostimulator

✓ tremors/dyskinesia
✓ mood
✓ impulse control
✓ cognition
✓ dysphagia

- balancing
- freezing of gait
- non-motor symptoms


![Mirza et al., 2017 Comparison GPI, STN; Figure from Lim, 2017](L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_14fa577dc5354adb.webp)</text>
    <formatted_text>#### Deep Brain Stimulation

Components: Electrode — Subthalamic nucleus (STN); Extension lead; Neurostimulator

Improvements:

- tremors/dyskinesia
- mood
- impulse control
- cognition
- dysphagia

Limited or no benefit:

- balancing
- freezing of gait
- non-motor symptoms</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="01:00:28" confidence="6" anchor="Limited or no benefit:  - balancing - freezing of gait - non-motor symptoms">
&gt; - ==Balance and freezing of gait may improve in some patients, along with other non-motor symptoms.==</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="54,47,913,940" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="diagram" path="L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_14fa577dc5354adb.webp" caption="Mirza et al., 2017 Comparison GPI, STN; Figure from Lim, 2017">
        <description>Labelled line drawing of a human head in profile showing the components and placement of a deep brain stimulation system, with arrows identifying the Electrode, Subthalamic nucleus (STN), Extension lead, and Neurostimulator. Two text boxes connected to the diagram list symptoms: a green box with checkmarks for 'tremors/dyskinesia', 'mood', 'impulse control', 'cognition', and 'dysphagia'; and an orange box with dashes for 'balancing', 'freezing of gait', and 'non-motor symptoms'.</description>
      </img>
    </images>
  </page>
  <page number="72">
    <text>Dentistry DBS incidents

• 2001 - Death of a dental patient with DBS and diathermy use
• 2006 - Severe infection of DBS reported due endodontic cause
• 2008 - Diathermy use in head &amp; neck region caused significant neural damage
• Some claims that majority of these incidents were not reported

Lim et al., 2017, Nutt et al., 2001; Sixel Döring et al., 2006, Roark et al., 2008

![](L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_c15434c06599ac35.webp)</text>
    <formatted_text>#### Dentistry DBS Incidents

- 2001 – Death of a dental patient with DBS and diathermy use
- 2006 – Severe infection of DBS reported due endodontic cause
- 2008 – Diathermy use in head &amp; neck region caused significant neural damage
- Some claims that majority of these incidents were not reported

*(Lim et al., 2017; Nutt et al., 2001; Sixel Döring et al., 2006; Roark et al., 2008)*</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="01:01:21" confidence="7" anchor="*(Lim et al., 2017; Nutt et al., 2001; Sixel Döring et al., 2006; Roark et al., ">

&gt; [!note] Lecturer — DBS Safety
&gt; A 2021 report described the death of a dental patient with deep brain stimulation after diathermy was used on the upper maxilla. The proposed explanation was that energy was absorbed by metal electrodes, heating parts of the brain.
&gt;
&gt; - Routine cleaning, scaling and extractions were described as unlikely to affect brain stimulation.
&gt; - Clinicians should check the literature or seek advice before treating patients with deep brain stimulation.
</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="114,271,458,869" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="diagram" path="L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_c15434c06599ac35.webp">
        <description>Line drawing of a patient's head and neck in profile, illustrating the anatomical placement of a Deep Brain Stimulation (DBS) system. The schematic depicts the intracranial electrode leads within the brain, the extension wires passing behind the ear down the neck, and the pulse generator implanted in the subclavicular region.</description>
      </img>
    </images>
  </page>
  <page number="73">
    <text>**Definition**

• Cerebral Palsy is an umbrella term encompassing a group of non-progressive neurological and physical disabilities
• caused by damage to a child’s brain early in the course of development,
  *in utero*, during birth or in the first few months of infancy.
• It is the most common congenital physical handicap</text>
    <formatted_text>- Cerebral Palsy is an umbrella term encompassing a group of non-progressive neurological and physical disabilities
- caused by damage to a child's brain early in the course of development, *in utero*, during birth or in the first few months of infancy.
- It is the most common congenital physical handicap</formatted_text>
  </page>
  <page number="74">
    <text># Aetiophysiology

*   Brain damage is caused mainly by hypoxia, trauma, infection, or hyperbilirubinaemia.
*   **Pre-natal risk:** pre-eclampsia, irradiation, a maternal age of less than 20 or over 35, various infections
*   **Peri-natal risk:** trauma, breech birth, prematurity or post-maturity
*   **Post-natal risk:** encephalitis, meningitis, kernicterus
*   **Other risk factors:** haemorrhage and hypoxia, respiratory distress, cerebral ischemia, hypothermia or hypoglycaemia</text>
    <formatted_text>- Brain damage is caused mainly by hypoxia, trauma, infection, or hyperbilirubinaemia.

- **Pre-natal risk:** pre-eclampsia, irradiation, a maternal age of less than 20 or over 35, various infections
- **Peri-natal risk:** trauma, breech birth, prematurity or post-maturity
- **Post-natal risk:** encephalitis, meningitis, kernicterus
- **Other risk factors:** haemorrhage and hypoxia, respiratory distress, cerebral ischemia, hypothermia or hypoglycaemia</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="01:02:49" confidence="5" anchor="- **Other risk factors:** haemorrhage and hypoxia, respiratory distress, cerebra">

&gt; [!note] Lecturer — Condition Classification
&gt; Cerebral palsy is a neurological and neurodevelopmental condition rather than a neurodegenerative condition.
</insert>
    </audio_inserts>
  </page>
  <page number="75">
    <text>**Epidermiology**

Cerebral palsy is the most common lifelong physical disability in the world, and people with cerebral palsy face significant barriers in everyday life.

**Cerebral Palsy in Australia: Key Facts**

*   **Prevalence:** It is estimated that around 37,000 people are living with cerebral palsy in Australia. Source:
*   The cost of cerebral palsy in Australia is an estimated $5.17 billion annually (as at 2019)
*   **Birth Rates:** Around 1 in 700 children in Australia are born with cerebral palsy.
*   **Mobility:** 63% of people with CP can walk independently, while 26% use a wheelchair.
*   **Geographic Diversity:** Around 30% of people with CP live in regional, rural, or remote areas, highlighting the need for equitable access to services.

*   roughly 50% have some level of intellectual disabilities
*   roughly 25-30% have epilepsy

Cerebral Palsy AUSTRALIA</text>
    <formatted_text>Cerebral palsy is the most common lifelong physical disability in the world, and people with cerebral palsy face significant barriers in everyday life.

#### Cerebral Palsy in Australia: Key Facts

- **Prevalence:** It is estimated that around 37,000 people are living with cerebral palsy in Australia.
- The cost of cerebral palsy in Australia is an estimated $5.17 billion annually (as at 2019)
- **Birth Rates:** Around 1 in 700 children in Australia are born with cerebral palsy.
- **Mobility:** 63% of people with CP can walk independently, while 26% use a wheelchair.
- **Geographic Diversity:** Around 30% of people with CP live in regional, rural, or remote areas, highlighting the need for equitable access to services.
- roughly 50% have some level of intellectual disabilities
- roughly 25-30% have epilepsy

*Cerebral Palsy Australia*</formatted_text>
  </page>
  <page number="76">
    <text>Types &amp; Presentation

The features of the four types of cerebral palsy (CP)

| Type of CP | %tage of all CP types | Site of damage | Features |
| :--- | :--- | :--- | :--- |
| Spastic | 55% | Cortex | Increased muscle tone and contractions of affected limbs. Complete/partial loss of control of muscle movement. Difficulties with head support&lt;br&gt;Difficulties with control and balance. Falls easily |
| Athetoid/ Dyskinetic | 15% (or 20-25%) | Basal ganglia | Smooth writhing movements as muscle tone fluctuates from increased to decreased tone&lt;br&gt;Constantly in motion High energy requirements&lt;br&gt;Movements exaggerated if anxious or an effort is made to control them |
| Ataxic | 10% | Cerebellum | Disordered short, jerky movements Difficulties with balance&lt;br&gt;Difficulties with walking and sitting straight Requires time to execute changes in position&lt;br&gt;Compromised co-ordination |
| Mixed | 10-15% | Some or all of the above | Some or all of the above&lt;br&gt;Tremor of all or part of the body Hypotonia of muscles&lt;br&gt;Inability to stand&lt;br&gt;Inability to raise the head |


![Table 1 from Lewis et al., 2008](L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_10c95ff6cbe29768.webp)</text>
    <formatted_text>The features of the four types of cerebral palsy (CP)

| Type of CP | % of all CP types | Site of damage | Features |
| :--- | :--- | :--- | :--- |
| Spastic | 55% | Cortex | Increased muscle tone and contractions of affected limbs. Complete/partial loss of control of muscle movement. Difficulties with head support. Difficulties with control and balance. Falls easily |
| Athetoid/Dyskinetic | 15% (or 20-25%) | Basal ganglia | Smooth writhing movements as muscle tone fluctuates from increased to decreased tone. Constantly in motion; high energy requirements. Movements exaggerated if anxious or an effort is made to control them |
| Ataxic | 10% | Cerebellum | Disordered short, jerky movements. Difficulties with balance. Difficulties with walking and sitting straight; requires time to execute changes in position. Compromised co-ordination |
| Mixed | 10-15% | Some or all of the above | Some or all of the above. Tremor of all or part of the body; hypotonia of muscles. Inability to stand. Inability to raise the head |</formatted_text>
    <images>
      <img order="0" bbox="10,204,985,903" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_10c95ff6cbe29768.webp" caption="Table 1 from Lewis et al., 2008">
        <description>A four-column table comparing the features of Spastic, Athetoid/Dyskinetic, Ataxic, and Mixed types of cerebral palsy. The columns detail the percentage of cases, site of brain damage (e.g., Cortex, Basal ganglia), and specific clinical characteristics such as muscle tone and movement patterns.</description>
      </img>
    </images>
  </page>
  <page number="77">
    <text>**Presentation**

1. Musculo-Skeletal disorders
   * abnormal walking gait
   * poor movement in hands
   * arthritis, dislocations, contractures and deformities

2. Other impairments
   * Hearing, visual, speech
   * Epilepsy
   * Learning disabilities
   * Difficulty in swallowing (drooling)

3. Secondary features
   * respiratory complications, angular chelitis from drooling
   * skin ulcers from pressure areas
   * digestive complications, reflux, constipation
   * bladder or kidney infections</text>
    <formatted_text>1. Musculo-skeletal disorders
   - abnormal walking gait
   - poor movement in hands
   - arthritis, dislocations, contractures and deformities

2. Other impairments
   - Hearing, visual, speech
   - Epilepsy
   - Learning disabilities
   - Difficulty in swallowing (drooling)

3. Secondary features
   - respiratory complications, angular cheilitis from drooling
   - skin ulcers from pressure areas
   - digestive complications, reflux, constipation
   - bladder or kidney infections</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="01:05:35" confidence="3" anchor="3. Secondary features    - respiratory complications, angular cheilitis from dro">
- ==Drooling may occur because patients have difficulty keeping saliva within the mouth and do not swallow frequently.==</insert>
    </audio_inserts>
  </page>
  <page number="78">
    <text>**Diagnosis**

*   Clinical signs:
    1. weakness in one or more limbs,
    2. abnormal gait with one foot or leg dragging,
    3. excessive drooling, difficulties in swallowing
    4. poor control over hand and arm movement

*   Imaging to show changes in the brain</text>
    <formatted_text>- Clinical signs:
  1. weakness in one or more limbs,
  2. abnormal gait with one foot or leg dragging,
  3. excessive drooling, difficulties in swallowing
  4. poor control over hand and arm movement

- Imaging to show changes in the brain</formatted_text>
  </page>
  <page number="79">
    <text># Diagnosis

Step reflex
Crawl reflex

images from www.abclawcenters.com

![Tonic neck reflex](L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_3791702e09b0d95f.webp)
![Grasp reflex](L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_a6822979df429a34.webp)
![Step reflex Crawl reflex](L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_4383e87a5ccfe85f.webp)
![Hypotonia (decreased muscle tone)](L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_4cc38b1f856b34a6.webp)</text>
    <formatted_text>Step reflex

Crawl reflex

*Images from www.abclawcenters.com*</formatted_text>
    <images>
      <img order="0" bbox="84,300,273,481" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_3791702e09b0d95f.webp" caption="Tonic neck reflex">
        <description>A clinical photograph of an infant lying supine on a white surface, demonstrating the tonic neck reflex (fencing posture). The baby's head is turned to one side, causing the arm on that side to extend outward while the opposite arm remains flexed near the head.</description>
      </img>
      <img order="1" bbox="285,297,452,478" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_a6822979df429a34.webp" caption="Grasp reflex">
        <description>A clinical photograph showing an adult finger placed in the palm of an infant's hand, demonstrating the grasp reflex where the baby's fingers curl tightly around the object.</description>
      </img>
      <img order="2" bbox="280,495,467,646" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_4383e87a5ccfe85f.webp" caption="Step reflex Crawl reflex">
        <description>A clinical photo of an infant lying prone on a surface, wearing a diaper, with arms and legs positioned to demonstrate the crawl reflex.</description>
      </img>
      <img order="3" bbox="552,269,934,677" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_4cc38b1f856b34a6.webp" caption="Hypotonia (decreased muscle tone)">
        <description>Clinical photos of an infant illustrating hypotonia, showing the baby with arms dangling limply when lifted by hands and the head lagging behind the body when suspended horizontally.</description>
      </img>
    </images>
  </page>
  <page number="80">
    <text>**General Management**

No cure
1. **Aids:** castings improve and maintain range of motion, wheelchair and aids improve independence
2. **Hip surveillance:** hip joint integrity
3. **Muscle spasticity:** botulin, diazepam, selective dorsal rhizotomy
4. **Bisphosphonates**
5. **Pressure care**
6. **Anti-epileptic medication**
7. **Constraint induced movement therapy-** Bimanual training, occupational therapy after botulin
8. **Fitness training**
9. **Bobath Therapy-x**</text>
    <formatted_text>No cure.

1. **Aids:** castings improve and maintain range of motion; wheelchair and aids improve independence
2. **Hip surveillance:** hip joint integrity
3. **Muscle spasticity:** botulin, diazepam, selective dorsal rhizotomy
4. **Bisphosphonates**
5. **Pressure care**
6. **Anti-epileptic medication**
7. **Constraint induced movement therapy:** bimanual training, occupational therapy after botulin
8. **Fitness training**
9. **Bobath Therapy**</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="01:07:46" confidence="10" anchor="7. **Constraint induced movement therapy:** bimanual training, occupational ther">

&gt; [!note] Lecturer — Management Details
&gt; Additional management considerations include the following:
&gt;
&gt; - Botulinum injection may also be used to reduce tooth grinding in some patients.
&gt; - Bisphosphonates may improve bone mineral density and help prevent fractures after falls.
&gt; - Pressure care is important because prolonged pressure can cause painful ulcers.
</insert>
    </audio_inserts>
  </page>
  <page number="81">
    <text>**Provision of Dental Care**

**Issues faced includes:**
*   Bruxism, attrition, TMJ dislocations. sleep apnea
*   Sialorrhea
*   Xerostomia, mouth breathing
*   Dysphagia
*   High arch palate
*   maxillary arch tapered, class II incisors</text>
    <formatted_text>Issues faced include:

- Bruxism, attrition, TMJ dislocations, sleep apnea
- Sialorrhea
- Xerostomia, mouth breathing
- Dysphagia
- High arch palate
- Maxillary arch tapered, class II incisors</formatted_text>
  </page>
  <page number="82">
    <text>**Provision of Dental Care**

**Issues faced includes (2):**
*   cooperation
*   poor coordination:
    *   poor lip seal;
    *   oro-musculature dyskinesia,
    *   tongue thrust and positioning,
    *   abnormal bite reflex
    *   lip trauma
    *   Dysphagia
*   communication difficulties</text>
    <formatted_text>Issues faced include (2):

- cooperation
- poor coordination:
  - poor lip seal
  - oro-musculature dyskinesia
  - tongue thrust and positioning
  - abnormal bite reflex
  - lip trauma
  - Dysphagia
- communication difficulties</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="01:09:26" confidence="4" anchor="- poor coordination:   - poor lip seal   - oro-musculature dyskinesia   - tongue">

&gt; [!note] Lecturer — Communication and Movement
&gt; Communication and movement findings require careful interpretation.
&gt;
&gt; - Inability to speak or communicate clearly does not necessarily indicate intellectual disability, so communication should be adapted carefully.
&gt; - Movement disorders can affect radiographs.
&gt; - Irregular involuntary movement in cerebral palsy contrasts with the shorter, lighter tremor and hunched posture seen in Parkinson's disease.
</insert>
    </audio_inserts>
  </page>
  <page number="83">
    <text>**Parkinson’s - neurodegenerative**

**NEUROLOGICAL DISORDERS**
**PRESENT WITH ABNORMAL**
**MOVEMENT (DYSKINESIA)**

*   Tremors
*   Chorea
*   Tics
*   Other involuntary movements


![Cerebral Palsy - neurodevelopmental](L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_36e6aadaa2561e75.webp)
![Parkinson’s - neurodegenerative](L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_ba72dde91ffc53dc.webp)</text>
    <formatted_text>Parkinson's — neurodegenerative.

#### Neurological Disorders Presenting with Abnormal Movement (Dyskinesia)

- Tremors
- Chorea
- Tics
- Other involuntary movements</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="01:10:15" confidence="3" anchor="- Tremors - Chorea - Tics - Other involuntary movements">
- ==Abnormal movement may affect dental procedures and radiographic imaging.==
- ==Different movement patterns may help distinguish presentations such as cerebral palsy, Parkinson's disease and Huntington's disease.==</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="1,0,494,804" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="image" path="L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_36e6aadaa2561e75.webp" caption="Cerebral Palsy - neurodevelopmental">
        <description>&quot;No discernible content is present.&quot;</description>
      </img>
      <img order="1" bbox="505,8,997,499" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_ba72dde91ffc53dc.webp" caption="Parkinson’s - neurodegenerative">
        <description>A blurry, black-and-white clinical photograph showing a close-up of a person's lower face and neck area. The image is characterized by significant motion blur, illustrating the involuntary tremors associated with Parkinson's disease.</description>
      </img>
    </images>
  </page>
  <page number="84">
    <text>Huntington’s Disease

*   is an inherited &lt;u&gt;degenerative neurological condition&lt;/u&gt; affecting the brain and central nervous system. It progressively impairs mental and physical abilities, eventually leading to the loss of critical functions such as walking, talking, eating and reasoning. Complications arising from HD ultimately resulting in death.
*   Features
    *   Uncontrollable dance-like movements (chorea). Rigidity subtypes are rare
    *   changes behaviour, emotion, judgement, personality, hallucinations
*   Causes:
    *   Mostly autosomal dominant, sometimes sporadic
    *   Mutation in Huntingtin gene, causing proteins to lodge in brain
*   Prognosis: no cure, progress over 2 decades
*   Epidemiology: 8-10 per 100,000 of European ancestry
*   Treatment:
    *   Supportive: exercise, healthy diet, psychosocial support
    *   Palliative concepts of treatment
    *   Medication to reduce symptoms (movement, mood etc.),

https://huntingtonsaustralia.au/about/
https://www.ninds.nih.gov/health-
information/disorders/huntingtons-
disease

![MakeAGIF](L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_4ad669feae614276.webp)</text>
    <formatted_text>Huntington's Disease is an inherited &lt;u&gt;degenerative neurological condition&lt;/u&gt; affecting the brain and central nervous system. It progressively impairs mental and physical abilities, eventually leading to the loss of critical functions such as walking, talking, eating and reasoning. Complications arising from HD ultimately resulting in death.

#### Features

- Uncontrollable dance-like movements (chorea). Rigidity subtypes are rare
- Changes behaviour, emotion, judgement, personality, hallucinations

#### Causes

- Mostly autosomal dominant, sometimes sporadic
- Mutation in Huntingtin gene, causing proteins to lodge in brain

#### Prognosis

- No cure; progresses over 2 decades

#### Epidemiology

- 8–10 per 100,000 of European ancestry

#### Treatment

- Supportive: exercise, healthy diet, psychosocial support
- Palliative concepts of treatment
- Medication to reduce symptoms (movement, mood etc.)

References: https://huntingtonsaustralia.au/about/ — https://www.ninds.nih.gov/health-information/disorders/huntingtons-disease</formatted_text>
    <audio_inserts count="4">
      <insert timestamp="01:11:52" confidence="3" anchor="- Uncontrollable dance-like movements (chorea). Rigidity subtypes are rare - Cha">
- ==Chorea may also involve writhing movements.==
- ==Later stages may include psychiatric conditions.==
- ==Walking may remain possible, but movement is difficult to control and maintain steadily.==</insert>
      <insert timestamp="01:12:46" confidence="6" anchor="- Mutation in Huntingtin gene, causing proteins to lodge in brain">

&gt; [!note] Lecturer — Huntington's Progression
&gt; The mutation causes proteins to misfold and lodge in the brain.
&gt;
&gt; - The disease was described as having a prion-like progression over many years.
</insert>
      <insert timestamp="01:11:21" confidence="2" anchor="- No cure; progresses over 2 decades">

&gt; [!note] Lecturer — Huntington's Mortality
&gt; Respiratory effects are an important cause of death in Huntington's disease.
</insert>
      <insert timestamp="01:13:27" confidence="2" anchor="- Medication to reduce symptoms (movement, mood etc.)">
- ==Spiritual support may form part of supportive treatment.==
- ==Antidepressants may be used.==
- ==Treatment is generally not invasive.==</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="664,672,999,910" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_4ad669feae614276.webp" caption="MakeAGIF">
        <description>A low-resolution video still or GIF frame showing a person from behind, wearing a blue shirt and light trousers, walking through an indoor doorway. In the context of the slide on Huntington's Disease, this image illustrates the gait disturbance or unsteady movement associated with the condition.</description>
      </img>
    </images>
  </page>
  <page number="85">
    <text># CASE EXAMPLE

**Medical History**
*   Huntingdon’s Disease (Dx 2000)
    *   Moderate Chorea
*   Dysphagia ( Severe )
    *   declined PEG
    *   Speech and Language Therapist, stabilised BMI

**Social History**
*   used to work + housekeep
*   Walking stick

**Dental History**
*   Moderate caries risk
*   Food pouching
*   Self-brushing after meals

MEDS: Tetrabenazine, Citalopram (SSRI)

**Management**
✓ I/O Exam with Clinical Holding/ Protective Stabilisation
✓ Shared-decision/informed consent
✓ Mild Sedation: 6mg Midazolam Orally, 20mins prior
✓ CAP 15 Distal Occlusal
✓ Water control
✓ Mouth prop</text>
    <formatted_text>#### Medical History

- Huntington's Disease (Dx 2000)
  - Moderate chorea
- Dysphagia (severe)
  - Declined PEG
  - Speech and Language Therapist, stabilised BMI

#### Social History

- Used to work + housekeep
- Walking stick

#### Dental History

- Moderate caries risk
- Food pouching
- Self-brushing after meals

MEDS: Tetrabenazine, Citalopram (SSRI)

#### Management

1. I/O exam with clinical holding / protective stabilisation
2. Shared-decision / informed consent
3. Mild sedation: 6mg Midazolam orally, 20mins prior
4. CAP 15 distal occlusal
5. Water control
6. Mouth prop</formatted_text>
    <audio_inserts count="4">
      <insert timestamp="01:15:27" confidence="6" anchor="- Speech and Language Therapist, stabilised BMI">

&gt; [!example] Huntington's Dysphagia Management
&gt; The patient declined percutaneous endoscopic gastrostomy feeding despite severe dysphagia.
&gt;
&gt; - Percutaneous endoscopic gastrostomy involves placing a feeding tube into the stomach.
&gt; - A nasogastric tube passes through the nose into the stomach.
&gt; - Her nutrition used high-calorie food and a diet appropriate to the current stage of dysphagia.
</insert>
      <insert timestamp="01:15:45" confidence="5" anchor="- Walking stick">
- ==She had previously worked as an accountant and later retired.==
- ==She performed housekeeping until the disease limited her ability to continue.==</insert>
      <insert timestamp="01:16:10" confidence="5" anchor="- Self-brushing after meals  MEDS: Tetrabenazine, Citalopram (SSRI)">

&gt; [!note] Lecturer — Oral Hygiene Challenges
&gt; Food accumulated in different areas of the mouth because of reduced movement ability.
&gt;
&gt; - Although she liked to brush after meals, she did not brush effectively.
&gt; - Tetrabenazine was used for Huntington's movements and the antidepressant was used for mood.
</insert>
      <insert timestamp="01:17:22" confidence="8" anchor="6. Mouth prop">

&gt; [!note] Lecturer — Sedation and Control
&gt; A small dose of benzodiazepine, 6 mg administered 20 minutes before treatment, produced useful movement control.
&gt;
&gt; - Rubber dam was used for upper posterior teeth during a prolonged procedure.
&gt; - The light sedation was sufficient to improve movement control.
</insert>
    </audio_inserts>
  </page>
  <page number="86">
    <text># How to learn about conditions

&lt;table&gt;
  &lt;thead&gt;
    &lt;tr&gt;
      &lt;th&gt;&lt;/th&gt;
      &lt;th&gt;Spina Bifida&lt;/th&gt;
      &lt;th&gt;Motor Neurone Disease&lt;/th&gt;
    &lt;/tr&gt;
  &lt;/thead&gt;
  &lt;tbody&gt;
    &lt;tr&gt;
      &lt;td&gt;Definition&lt;/td&gt;
      &lt;td&gt;&lt;/td&gt;
      &lt;td&gt;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;Epidemiology&lt;/td&gt;
      &lt;td&gt;&lt;/td&gt;
      &lt;td&gt;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;Clinical features&lt;/td&gt;
      &lt;td&gt;&lt;/td&gt;
      &lt;td&gt;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;Aetiopathogensis&lt;/td&gt;
      &lt;td&gt;&lt;/td&gt;
      &lt;td&gt;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;Diagnosis / Types&lt;/td&gt;
      &lt;td&gt;&lt;/td&gt;
      &lt;td&gt;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;Management / Prognosis&lt;/td&gt;
      &lt;td&gt;&lt;/td&gt;
      &lt;td&gt;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;Oral findings&lt;/td&gt;
      &lt;td&gt;&lt;/td&gt;
      &lt;td&gt;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;Emergencies&lt;/td&gt;
      &lt;td&gt;&lt;/td&gt;
      &lt;td&gt;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;ACCESS&lt;/td&gt;
      &lt;td&gt;&lt;/td&gt;
      &lt;td&gt;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;/tbody&gt;
&lt;/table&gt;

![](L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_8fd791de25c24bba.webp)</text>
    <formatted_text>#### How to learn about conditions

Complete the following template for each condition:

| | Spina Bifida | Motor Neurone Disease |
|---|---|---|
| Definition | | |
| Epidemiology | | |
| Clinical features | | |
| Aetiopathogenesis | | |
| Diagnosis / Types | | |
| Management / Prognosis | | |
| Oral findings | | |
| Emergencies | | |
| ACCESS | | |</formatted_text>
    <images>
      <img order="0" bbox="44,157,960,996" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_8fd791de25c24bba.webp">
        <description>A blank comparison table with columns for &quot;Spina Bifida&quot; and &quot;Motor Neurone Disease&quot;. The rows list specific categories to be filled in, including Definition, Epidemiology, Clinical features, Aetiopathogensis, Diagnosis / Types, Management / Prognosis, Oral findings, Emergencies, and ACCESS.</description>
      </img>
    </images>
  </page>
  <page number="87">
    <text>&lt;table&gt;
  &lt;tr&gt;
    &lt;th&gt;&lt;/th&gt;
    &lt;th&gt;Where to find basic info&lt;/th&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Epilepsy&lt;/td&gt;
    &lt;td&gt;Slides&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Cerebral palsy&lt;/td&gt;
    &lt;td&gt;Slides&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Stroke&lt;/td&gt;
    &lt;td&gt;Dougall &amp;amp; Fiske 2008 https://www.nature.com/articles/sj.bdj.2008.891&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Parkinson’s disease&lt;/td&gt;
    &lt;td&gt;Slides&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Motor neurone disease&lt;/td&gt;
    &lt;td&gt;Tay &amp;amp; Borromeo 2014 https://onlinelibrary.wiley.com/doi/10.1111/dj&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Multiple sclerosis&lt;/td&gt;
    &lt;td&gt;Slides&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Huntington’s&lt;/td&gt;
    &lt;td&gt;Slides&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Acquired brain injury&lt;/td&gt;
    &lt;td&gt;Kothari et al., 2020 https://www.tandfonline.com/doi/epdf/8/6&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Spina Bifida&lt;/td&gt;
    &lt;td&gt;Gary et al., 2012 https://onlinelibrary.wiley.com/doi/10.1111/j&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

![](L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_7ca05d295a839c11.webp)</text>
    <formatted_text>| Condition | Where to find basic info |
|---|---|
| Epilepsy | Slides |
| Cerebral palsy | Slides |
| Stroke | Dougall &amp; Fiske 2008 — https://www.nature.com/articles/sj.bdj.2008.891 |
| Parkinson's disease | Slides |
| Motor neurone disease | Tay &amp; Borromeo 2014 — https://onlinelibrary.wiley.com/doi/10.1111/dj |
| Multiple sclerosis | Slides |
| Huntington's | Slides |
| Acquired brain injury | Kothari et al., 2020 — https://www.tandfonline.com/doi/epdf/8/6 |
| Spina Bifida | Gary et al., 2012 — https://onlinelibrary.wiley.com/doi/10.1111/j |</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="01:18:26" confidence="6" anchor="| Spina Bifida | Gary et al., 2012 — https://onlinelibrary.wiley.com/doi/10.1111">

&gt; [!note] Lecturer — Independent Study
&gt; Students were encouraged to use the provided material and independently research the conditions. Google and ChatGPT could be used as resources.
&gt;
&gt; - Students were advised to work through the exercises themselves to support learning and preparation for multiple-choice examinations.
</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="62,83,938,947" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_7ca05d295a839c11.webp">
        <description>A two-column table listing various neurological and developmental conditions alongside their respective information sources. The left column includes conditions such as Epilepsy, Stroke, Parkinson's disease, and Spina Bifida, while the right column indicates where to find basic info, citing either 'Slides' or specific academic articles with URLs.</description>
      </img>
    </images>
  </page>
  <page number="88">
    <text>Things for you to do

6. Geriatric Medicine and Dentistry - Leung 2025
Enabled: Statistics Tracking

7. Oncology and Palliative Care - Sundaresan 2020
Enabled: Statistics Tracking

7. Oncology and Palliative Care - Sundaresan 2020
Enabled: Statistics Tracking

8. Neurodegenerative Disease (quiz) - 2025
Availability: Item is hidden from students.
Following the lecture on 15 Sep 2025 (Mon), this quiz strengthens your learning.
LECTURE LEARNING OBJECTIVES:
1. Understand the specific characteristics and dental needs of individuals with common Parkinson's disease, motor neurone disease, multiple sclerosis, Huntington's disease, ensure effective dental care.

INSTRUCTIONS

Description
Following the lecture on 15 Sep 2025 (Mon), this quiz strengthens your learning.
Please allocate around **30 minutes** for this quiz. This is an individual quiz.
LECTURE LEARNING OBJECTIVES:
1. Understand the specific characteristics and dental needs of individuals with common neurodegenerative diseases (e.g. epilepsy, Parkinson's disease, motor neurone disease, multiple sclerosis, Huntington's disease, spina bifida), including communication strategies and adaptations to ensure effective dental care.

Instructions
Please complete all questions in this assignment and submit them by **19 Sep 2025 (Friday) 1159pm**.
This is an open book assignment, please utilise resources at your disposal.
This is an individual assignment, not a group work. It trains your thinking process and would help in your assessment in this Unit.
There is no time limit, but generally students take 15-30 minutes. Please submit by the deadline above. Thank you and enjoy learning!

Force Completion
This test can be saved and resumed later.

Due Date
This Test is due on 19 September 2025 11:59:00 PM AWST.

Click **Begin** to start: 8. Neurodegenerative Disease (quiz) - 2025. Click **Cancel** to go back.
You will be previewing this assessment and your results will not be recorded.

![](L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_29242a37f09d6813.webp)
![Begin: 8. Neurodegenerative Disease (quiz) - 2025](L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_ae0e832f2242a6d7.webp)</text>
    <formatted_text>#### Things for you to do

- 6. Geriatric Medicine and Dentistry - Leung 2025 — Enabled: Statistics Tracking
- 7. Oncology and Palliative Care - Sundaresan 2020 — Enabled: Statistics Tracking
- 8. Neurodegenerative Disease (quiz) - 2025 — Availability: Item is hidden from students.

#### Quiz Description

Following the lecture on 15 Sep 2025 (Mon), this quiz strengthens your learning. Please allocate around **30 minutes** for this quiz. This is an individual quiz.

**Lecture learning objectives:**

1. Understand the specific characteristics and dental needs of individuals with common neurodegenerative diseases (e.g. epilepsy, Parkinson's disease, motor neurone disease, multiple sclerosis, Huntington's disease, spina bifida), including communication strategies and adaptations to ensure effective dental care.

#### Instructions

- Please complete all questions in this assignment and submit them by **19 Sep 2025 (Friday) 11:59pm**.
- This is an open book assignment, please utilise resources at your disposal.
- This is an individual assignment, not group work. It trains your thinking process and would help in your assessment in this Unit.
- There is no time limit, but generally students take 15-30 minutes. Please submit by the deadline above. Thank you and enjoy learning!

#### Test Settings

- **Force Completion:** This test can be saved and resumed later.
- **Due Date:** This Test is due on 19 September 2025 11:59:00 PM AWST.

Click **Begin** to start: 8. Neurodegenerative Disease (quiz) - 2025. Click **Cancel** to go back.

&gt; You will be previewing this assessment and your results will not be recorded.</formatted_text>
    <audio_inserts count="2">
      <insert timestamp="01:18:03" confidence="7" anchor="- 8. Neurodegenerative Disease (quiz) - 2025 — Availability: Item is hidden from">
- ==Review the conditions not covered in detail, including motor neuron disease, acquired brain injury, and spina bifida.==
- ==Use a table or spreadsheet to organise information about each condition.==</insert>
      <insert timestamp="01:18:26" confidence="3" anchor="- There is no time limit, but generally students take 15-30 minutes. Please subm">
- ==Work through the mental processes rather than simply obtaining answers.==</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="537,254,555,289" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="image" path="L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_29242a37f09d6813.webp">
        <description>No discernible content is present.</description>
      </img>
      <img order="1" bbox="34,485,998,969" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="figure" path="L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_ae0e832f2242a6d7.webp" caption="Begin: 8. Neurodegenerative Disease (quiz) - 2025">
        <description>The image displays a text-based information panel for an online quiz titled &quot;8. Neurodegenerative Disease (quiz) - 2025&quot;. It includes sections for Description, Instructions, Force Completion, and Due Date, outlining the learning objectives related to dental care for patients with conditions like Parkinson's disease and motor neurone disease.</description>
      </img>
    </images>
  </page>
  <page number="89">
    <text>&lt;b&gt;Module 5311 (Special Needs Dentistry)&lt;/b&gt;

&lt;i&gt;Neurodegenerative disease&lt;/i&gt;
Thank you

guangxudavid.lim@uwa.edu.au
jeeyun.leung@uwa.edu.au (unit coordinator)

&lt;b&gt;15 Sep 2025&lt;/b&gt;
&lt;b&gt;2-4 PM (WA Time)&lt;/b&gt;
&lt;b&gt;Online&lt;/b&gt;

&lt;b&gt;Dr David Lim&lt;/b&gt;
Lecturer, Dental School, UWA
BDS (SG), MSc SCD (UCL), PG Dip Con Sed D (KCL), GC Geront (SUSS), Dip ACEdu (SUSS),
FiADH, MFTD MFDS RCSEd
Acknowledgements to: Dr Daniel Sundaresan, AProf Mina Borromeo, Dr Matthew Lim, Dr
Claudia Lopez Silva

UWA
PERTH • AUSTRALIA</text>
    <formatted_text>**Module 5311 (Special Needs Dentistry)** — *Neurodegenerative disease*

Thank you

- guangxudavid.lim@uwa.edu.au
- jeeyun.leung@uwa.edu.au (unit coordinator)

**15 Sep 2025**

**2-4 PM (WA Time)**

**Online**

**Dr David Lim**
Lecturer, Dental School, UWA
BDS (SG), MSc SCD (UCL), PG Dip Con Sed D (KCL), GC Geront (SUSS), Dip ACEdu (SUSS), FiADH, MFTD MFDS RCSEd

Acknowledgements to: Dr Daniel Sundaresan, AProf Mina Borromeo, Dr Matthew Lim, Dr Claudia Lopez Silva

UWA — Perth • Australia</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="01:18:57" confidence="6" anchor="- jeeyun.leung@uwa.edu.au (unit coordinator)  **15 Sep 2025**  **2-4 PM (WA Time">

&gt; [!note] Lecturer — Contact Questions
&gt; Questions could be directed to the lecturer by email.
&gt;
&gt; - Module-related questions could be directed to Dr. Jiyoon using the provided email address.
</insert>
    </audio_inserts>
  </page>
  <page number="90" origin="cases">
    <text>## Case: Dental patient with DBS who died after diathermy use

### Question

**Scenario:** A dental patient with a deep brain stimulation (DBS) device.

**What's shown:** A reported incident involving the use of diathermy in a patient with a DBS device.

**Consider:** What was the outcome of the procedure and the proposed mechanism of injury?

### Answer

**Observations:**
- Diathermy was used on the upper maxilla.
- The treatment site was reportedly close to the DBS electrodes.

**Reasoning:** The energy from the diathermy was absorbed by the metal electrodes, heating parts of the brain and causing overheating.

**Outcome:** The patient died due to the overheating.

**Takeaway:** Diathermy use near DBS electrodes can be fatal due to energy absorption and brain overheating.

## Case: Dental patient with DBS who developed severe infection after endodontic procedure

### Question

**Scenario:** A dental patient with a deep brain stimulation (DBS) device.

**What's shown:** A reported incident involving an endodontic procedure in a patient with a DBS device.

**Consider:** What complication occurred following the procedure?


### Answer

**Observations:**
- The patient developed a severe infection of the DBS device.
- Bacteria were cultured from the infection.

**Reasoning:** The endodontic procedure was reported as the cause of the severe infection in the DBS device.

**Outcome:** The patient developed a severe DBS infection; bacteria were cultured.

**Takeaway:** Endodontic procedures can lead to severe infections of deep brain stimulation devices.

## Case: OPG of a patient with Parkinson's disease

### Question

**Scenario:** A patient with Parkinson's disease is undergoing an orthopantomogram (OPG).

**What's shown:** An OPG radiograph showing soft tissue movements and a curved image.

**Consider:** What findings are visible on the radiograph, and how do they relate to the patient's condition?

### Answer

**Observations:**
- A short, light tremor with soft tissue movements.
- The patient has a very hunched back.
- The resulting OPG image has a curve.

**Reasoning:** The short, light tremor causes soft tissue movement artifacts. Additionally, the hunched posture, which is characteristic of advanced Parkinson's disease, prevents the OPG machine from passing across the back properly, resulting in a curved image.

**Takeaway:** Movement disorders and postural changes, such as the hunched posture in advanced Parkinson's disease, can physically interfere with X-ray equipment and affect the resulting image.

## Case: OPG of a patient with cerebral palsy

### Question

**Scenario:** A patient with cerebral palsy is undergoing an orthopantomogram (OPG).

**What's shown:** An OPG radiograph of a patient exhibiting involuntary movements.

**Consider:** What findings are visible on the radiograph, and how do they relate to the patient's condition?


### Answer

**Observations:**
- An irregular tremor and involuntary movements are visible on the image.

**Reasoning:** The irregular tremor is characteristic of the involuntary movements associated with cerebral palsy, which can introduce movement artifacts into the radiograph.

**Takeaway:** Movement disorders such as cerebral palsy can affect X-ray taking due to involuntary movements.

## Case: Patient with Huntington's disease undergoing dental treatment

### Question

**Scenario:** A female patient with a history of Huntington's disease (diagnosed in 2000) presents for dental care. She experiences moderate chorea (writhing movements) and severe dysphagia, which she manages with a speech and language therapist and a modified diet after declining a PEG tube. She has a moderate caries risk with food pouching and takes tetrabenazine and citalopram.

**What's shown:** The patient's medical, social, and dental history, alongside the planned management for her dental appointment.

**Consider:** How was this patient managed intraorally to facilitate dental treatment and control her involuntary movements?
</text>
    <formatted_text>## Case: Dental patient with DBS who died after diathermy use

### Question

**Scenario:** A dental patient with a deep brain stimulation (DBS) device.

**What's shown:** A reported incident involving the use of diathermy in a patient with a DBS device.

**Consider:** What was the outcome of the procedure and the proposed mechanism of injury?

### Answer

**Observations:**
- Diathermy was used on the upper maxilla.
- The treatment site was reportedly close to the DBS electrodes.

**Reasoning:** The energy from the diathermy was absorbed by the metal electrodes, heating parts of the brain and causing overheating.

**Outcome:** The patient died due to the overheating.

**Takeaway:** Diathermy use near DBS electrodes can be fatal due to energy absorption and brain overheating.

## Case: Dental patient with DBS who developed severe infection after endodontic procedure

### Question

**Scenario:** A dental patient with a deep brain stimulation (DBS) device.

**What's shown:** A reported incident involving an endodontic procedure in a patient with a DBS device.

**Consider:** What complication occurred following the procedure?


![](L11  Neurodegenerative disease DMD3 Lecture notes_cases_attachments/img_c15434c06599ac35.webp)
### Answer

**Observations:**
- The patient developed a severe infection of the DBS device.
- Bacteria were cultured from the infection.

**Reasoning:** The endodontic procedure was reported as the cause of the severe infection in the DBS device.

**Outcome:** The patient developed a severe DBS infection; bacteria were cultured.

**Takeaway:** Endodontic procedures can lead to severe infections of deep brain stimulation devices.

## Case: OPG of a patient with Parkinson's disease

### Question

**Scenario:** A patient with Parkinson's disease is undergoing an orthopantomogram (OPG).

**What's shown:** An OPG radiograph showing soft tissue movements and a curved image.

**Consider:** What findings are visible on the radiograph, and how do they relate to the patient's condition?

### Answer

**Observations:**
- A short, light tremor with soft tissue movements.
- The patient has a very hunched back.
- The resulting OPG image has a curve.

**Reasoning:** The short, light tremor causes soft tissue movement artifacts. Additionally, the hunched posture, which is characteristic of advanced Parkinson's disease, prevents the OPG machine from passing across the back properly, resulting in a curved image.

**Takeaway:** Movement disorders and postural changes, such as the hunched posture in advanced Parkinson's disease, can physically interfere with X-ray equipment and affect the resulting image.

## Case: OPG of a patient with cerebral palsy

### Question

**Scenario:** A patient with cerebral palsy is undergoing an orthopantomogram (OPG).

**What's shown:** An OPG radiograph of a patient exhibiting involuntary movements.

**Consider:** What findings are visible on the radiograph, and how do they relate to the patient's condition?


![](L11  Neurodegenerative disease DMD3 Lecture notes_cases_attachments/img_ba72dde91ffc53dc.webp)
### Answer

**Observations:**
- An irregular tremor and involuntary movements are visible on the image.

**Reasoning:** The irregular tremor is characteristic of the involuntary movements associated with cerebral palsy, which can introduce movement artifacts into the radiograph.

**Takeaway:** Movement disorders such as cerebral palsy can affect X-ray taking due to involuntary movements.

## Case: Patient with Huntington's disease undergoing dental treatment

### Question

**Scenario:** A female patient with a history of Huntington's disease (diagnosed in 2000) presents for dental care. She experiences moderate chorea (writhing movements) and severe dysphagia, which she manages with a speech and language therapist and a modified diet after declining a PEG tube. She has a moderate caries risk with food pouching and takes tetrabenazine and citalopram.

**What's shown:** The patient's medical, social, and dental history, alongside the planned management for her dental appointment.

**Consider:** How was this patient managed intraorally to facilitate dental treatment and control her involuntary movements?
</formatted_text>
    <heading_path>Case: Dental patient with DBS who died after diathermy use</heading_path>
    <images>
      <img order="0" type="diagram" path="L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_c15434c06599ac35.webp" media="frame" source="slide" page="72" timestamp="01:00:56">
        <description>Line drawing of a patient's head and neck in profile, illustrating the anatomical placement of a Deep Brain Stimulation (DBS) system. The schematic depicts the intracranial electrode leads within the brain, the extension wires passing behind the ear down the neck, and the pulse generator implanted in the subclavicular region.</description>
      </img>
      <img order="1" type="photo" path="L11  Neurodegenerative disease DMD3 Lecture notes_figures/img_ba72dde91ffc53dc.webp" media="frame" source="slide" page="83" timestamp="01:09:46">
        <description>Parkinson’s - neurodegenerative A blurry, black-and-white clinical photograph showing a close-up of a person's lower face and neck area. The image is characterized by significant motion blur, illustrating the involuntary tremors associated with Parkinson's disease.</description>
      </img>
    </images>
  </page>
  <page number="91" origin="cases">
    <text>### Answer

**Observations:**
- Moderate chorea and severe dysphagia.
- Moderate caries risk with food pouching.
- Medications include tetrabenazine (for movement) and citalopram (antidepressant).

**Reasoning:** 
- The patient's involuntary movements require careful management and stabilization to safely conduct an intraoral examination and perform dental treatment.
- Clinical holding and protective stabilization were utilized for the examination.
- To achieve good movement control for a prolonged procedure, a very light level of oral sedation was administered.

**Outcome:** 
- The patient was given 6mg of oral midazolam 20 minutes prior to treatment, which successfully controlled her movements.
- For the prolonged procedure on the upper posterior teeth, a rubber dam, water control, and a mouth prop were used to assist with the treatment.

**Takeaway:** 
- Patients with Huntington's disease and chorea can be managed effectively in the dental chair using a combination of protective stabilization, mild oral sedation, and practical aids like a rubber dam and mouth prop to control movement and ensure safety during treatment.
</text>
    <formatted_text>### Answer

**Observations:**
- Moderate chorea and severe dysphagia.
- Moderate caries risk with food pouching.
- Medications include tetrabenazine (for movement) and citalopram (antidepressant).

**Reasoning:** 
- The patient's involuntary movements require careful management and stabilization to safely conduct an intraoral examination and perform dental treatment.
- Clinical holding and protective stabilization were utilized for the examination.
- To achieve good movement control for a prolonged procedure, a very light level of oral sedation was administered.

**Outcome:** 
- The patient was given 6mg of oral midazolam 20 minutes prior to treatment, which successfully controlled her movements.
- For the prolonged procedure on the upper posterior teeth, a rubber dam, water control, and a mouth prop were used to assist with the treatment.

**Takeaway:** 
- Patients with Huntington's disease and chorea can be managed effectively in the dental chair using a combination of protective stabilization, mild oral sedation, and practical aids like a rubber dam and mouth prop to control movement and ensure safety during treatment.
</formatted_text>
    <heading_path>Case: Patient with Huntington's disease undergoing dental treatment &gt; Answer</heading_path>
  </page>
  <footnotes>[^1]: Original PDF page 1: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=1|L11  Neurodegenerative disease DMD3 Lecture notes, p.1]]
[^2]: Original PDF page 2: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=2|L11  Neurodegenerative disease DMD3 Lecture notes, p.2]]
[^3]: Original PDF page 3: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=3|L11  Neurodegenerative disease DMD3 Lecture notes, p.3]]
[^4]: Original PDF page 4: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=4|L11  Neurodegenerative disease DMD3 Lecture notes, p.4]]
[^5]: Original PDF page 5: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=5|L11  Neurodegenerative disease DMD3 Lecture notes, p.5]]
[^6]: Original PDF page 6: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=6|L11  Neurodegenerative disease DMD3 Lecture notes, p.6]]
[^7]: Original PDF page 7: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=7|L11  Neurodegenerative disease DMD3 Lecture notes, p.7]]
[^8]: Original PDF page 8: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=8|L11  Neurodegenerative disease DMD3 Lecture notes, p.8]]
[^9]: Original PDF page 9: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=9|L11  Neurodegenerative disease DMD3 Lecture notes, p.9]]
[^10]: Original PDF page 10: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=10|L11  Neurodegenerative disease DMD3 Lecture notes, p.10]]
[^11]: Original PDF page 11: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=11|L11  Neurodegenerative disease DMD3 Lecture notes, p.11]]
[^12]: Original PDF page 12: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=12|L11  Neurodegenerative disease DMD3 Lecture notes, p.12]]
[^13]: Original PDF page 13: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=13|L11  Neurodegenerative disease DMD3 Lecture notes, p.13]]
[^14]: Original PDF page 14: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=14|L11  Neurodegenerative disease DMD3 Lecture notes, p.14]]
[^15]: Original PDF page 15: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=15|L11  Neurodegenerative disease DMD3 Lecture notes, p.15]]
[^16]: Original PDF page 16: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=16|L11  Neurodegenerative disease DMD3 Lecture notes, p.16]]
[^17]: Original PDF page 17: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=17|L11  Neurodegenerative disease DMD3 Lecture notes, p.17]]
[^18]: Original PDF page 18: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=18|L11  Neurodegenerative disease DMD3 Lecture notes, p.18]]
[^19]: Original PDF page 19: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=19|L11  Neurodegenerative disease DMD3 Lecture notes, p.19]]
[^20]: Original PDF page 20: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=20|L11  Neurodegenerative disease DMD3 Lecture notes, p.20]]
[^21]: Original PDF page 21: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=21|L11  Neurodegenerative disease DMD3 Lecture notes, p.21]]
[^22]: Original PDF page 22: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=22|L11  Neurodegenerative disease DMD3 Lecture notes, p.22]]
[^23]: Original PDF page 23: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=23|L11  Neurodegenerative disease DMD3 Lecture notes, p.23]]
[^24]: Original PDF page 24: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=24|L11  Neurodegenerative disease DMD3 Lecture notes, p.24]]
[^25]: Original PDF page 25: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=25|L11  Neurodegenerative disease DMD3 Lecture notes, p.25]]
[^26]: Original PDF page 26: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=26|L11  Neurodegenerative disease DMD3 Lecture notes, p.26]]
[^27]: Original PDF page 27: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=27|L11  Neurodegenerative disease DMD3 Lecture notes, p.27]]
[^28]: Original PDF page 28: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=28|L11  Neurodegenerative disease DMD3 Lecture notes, p.28]]
[^29]: Original PDF page 29: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=29|L11  Neurodegenerative disease DMD3 Lecture notes, p.29]]
[^30]: Original PDF page 30: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=30|L11  Neurodegenerative disease DMD3 Lecture notes, p.30]]
[^31]: Original PDF page 31: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=31|L11  Neurodegenerative disease DMD3 Lecture notes, p.31]]
[^32]: Original PDF page 32: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=32|L11  Neurodegenerative disease DMD3 Lecture notes, p.32]]
[^33]: Original PDF page 33: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=33|L11  Neurodegenerative disease DMD3 Lecture notes, p.33]]
[^34]: Original PDF page 34: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=34|L11  Neurodegenerative disease DMD3 Lecture notes, p.34]]
[^35]: Original PDF page 35: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=35|L11  Neurodegenerative disease DMD3 Lecture notes, p.35]]
[^36]: Original PDF page 36: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=36|L11  Neurodegenerative disease DMD3 Lecture notes, p.36]]
[^37]: Original PDF page 37: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=37|L11  Neurodegenerative disease DMD3 Lecture notes, p.37]]
[^38]: Original PDF page 38: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=38|L11  Neurodegenerative disease DMD3 Lecture notes, p.38]]
[^39]: Original PDF page 39: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=39|L11  Neurodegenerative disease DMD3 Lecture notes, p.39]]
[^40]: Original PDF page 40: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=40|L11  Neurodegenerative disease DMD3 Lecture notes, p.40]]
[^41]: Original PDF page 41: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=41|L11  Neurodegenerative disease DMD3 Lecture notes, p.41]]
[^42]: Original PDF page 42: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=42|L11  Neurodegenerative disease DMD3 Lecture notes, p.42]]
[^43]: Original PDF page 43: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=43|L11  Neurodegenerative disease DMD3 Lecture notes, p.43]]
[^44]: Original PDF page 44: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=44|L11  Neurodegenerative disease DMD3 Lecture notes, p.44]]
[^45]: Original PDF page 45: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=45|L11  Neurodegenerative disease DMD3 Lecture notes, p.45]]
[^46]: Original PDF page 46: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=46|L11  Neurodegenerative disease DMD3 Lecture notes, p.46]]
[^47]: Original PDF page 47: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=47|L11  Neurodegenerative disease DMD3 Lecture notes, p.47]]
[^48]: Original PDF page 48: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=48|L11  Neurodegenerative disease DMD3 Lecture notes, p.48]]
[^49]: Original PDF page 49: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=49|L11  Neurodegenerative disease DMD3 Lecture notes, p.49]]
[^50]: Original PDF page 50: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=50|L11  Neurodegenerative disease DMD3 Lecture notes, p.50]]
[^51]: Original PDF page 51: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=51|L11  Neurodegenerative disease DMD3 Lecture notes, p.51]]
[^52]: Original PDF page 52: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=52|L11  Neurodegenerative disease DMD3 Lecture notes, p.52]]
[^53]: Original PDF page 53: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=53|L11  Neurodegenerative disease DMD3 Lecture notes, p.53]]
[^54]: Original PDF page 54: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=54|L11  Neurodegenerative disease DMD3 Lecture notes, p.54]]
[^55]: Original PDF page 55: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=55|L11  Neurodegenerative disease DMD3 Lecture notes, p.55]]
[^56]: Original PDF page 56: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=56|L11  Neurodegenerative disease DMD3 Lecture notes, p.56]]
[^57]: Original PDF page 57: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=57|L11  Neurodegenerative disease DMD3 Lecture notes, p.57]]
[^58]: Original PDF page 58: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=58|L11  Neurodegenerative disease DMD3 Lecture notes, p.58]]
[^59]: Original PDF page 59: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=59|L11  Neurodegenerative disease DMD3 Lecture notes, p.59]]
[^60]: Original PDF page 60: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=60|L11  Neurodegenerative disease DMD3 Lecture notes, p.60]]
[^61]: Original PDF page 61: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=61|L11  Neurodegenerative disease DMD3 Lecture notes, p.61]]
[^62]: Original PDF page 62: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=62|L11  Neurodegenerative disease DMD3 Lecture notes, p.62]]
[^63]: Original PDF page 63: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=63|L11  Neurodegenerative disease DMD3 Lecture notes, p.63]]
[^64]: Original PDF page 64: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=64|L11  Neurodegenerative disease DMD3 Lecture notes, p.64]]
[^65]: Original PDF page 65: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=65|L11  Neurodegenerative disease DMD3 Lecture notes, p.65]]
[^66]: Original PDF page 66: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=66|L11  Neurodegenerative disease DMD3 Lecture notes, p.66]]
[^67]: Original PDF page 67: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=67|L11  Neurodegenerative disease DMD3 Lecture notes, p.67]]
[^68]: Original PDF page 68: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=68|L11  Neurodegenerative disease DMD3 Lecture notes, p.68]]
[^69]: Original PDF page 69: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=69|L11  Neurodegenerative disease DMD3 Lecture notes, p.69]]
[^70]: Original PDF page 70: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=70|L11  Neurodegenerative disease DMD3 Lecture notes, p.70]]
[^71]: Original PDF page 71: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=71|L11  Neurodegenerative disease DMD3 Lecture notes, p.71]]
[^72]: Original PDF page 72: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=72|L11  Neurodegenerative disease DMD3 Lecture notes, p.72]]
[^73]: Original PDF page 73: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=73|L11  Neurodegenerative disease DMD3 Lecture notes, p.73]]
[^74]: Original PDF page 74: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=74|L11  Neurodegenerative disease DMD3 Lecture notes, p.74]]
[^75]: Original PDF page 75: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=75|L11  Neurodegenerative disease DMD3 Lecture notes, p.75]]
[^76]: Original PDF page 76: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=76|L11  Neurodegenerative disease DMD3 Lecture notes, p.76]]
[^77]: Original PDF page 77: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=77|L11  Neurodegenerative disease DMD3 Lecture notes, p.77]]
[^78]: Original PDF page 78: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=78|L11  Neurodegenerative disease DMD3 Lecture notes, p.78]]
[^79]: Original PDF page 79: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=79|L11  Neurodegenerative disease DMD3 Lecture notes, p.79]]
[^80]: Original PDF page 80: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=80|L11  Neurodegenerative disease DMD3 Lecture notes, p.80]]
[^81]: Original PDF page 81: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=81|L11  Neurodegenerative disease DMD3 Lecture notes, p.81]]
[^82]: Original PDF page 82: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=82|L11  Neurodegenerative disease DMD3 Lecture notes, p.82]]
[^83]: Original PDF page 83: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=83|L11  Neurodegenerative disease DMD3 Lecture notes, p.83]]
[^84]: Original PDF page 84: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=84|L11  Neurodegenerative disease DMD3 Lecture notes, p.84]]
[^85]: Original PDF page 85: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=85|L11  Neurodegenerative disease DMD3 Lecture notes, p.85]]
[^86]: Original PDF page 86: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=86|L11  Neurodegenerative disease DMD3 Lecture notes, p.86]]
[^87]: Original PDF page 87: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=87|L11  Neurodegenerative disease DMD3 Lecture notes, p.87]]
[^88]: Original PDF page 88: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=88|L11  Neurodegenerative disease DMD3 Lecture notes, p.88]]
[^89]: Original PDF page 89: [[L11  Neurodegenerative disease DMD3 Lecture notes.pdf#page=89|L11  Neurodegenerative disease DMD3 Lecture notes, p.89]]</footnotes>
</document>
